BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J;  ABC-02 Trial Investigators. Cisplatin plus gemcitabine vs gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273-1281. [PMID: 20375404 DOI: 10.1056/nejmoa0908721] [Cited by in Crossref: 1959] [Cited by in F6Publishing: 1012] [Article Influence: 163.3] [Reference Citation Analysis]
Number Citing Articles
1 Kang J, Jeong JH, Hwang HS, Lee SS, Park DH, Oh DW, Song TJ, Kim KH, Hwang S, Hwang DW, Kim SC, Park JH, Hong SM, Kim KP, Ryoo BY, Yoo C. Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. Cancer Res Treat 2020;52:594-603. [PMID: 32019287 DOI: 10.4143/crt.2019.493] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
2 Miao L, Guo S, Zhang J, Kim WY, Huang L. Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer. Adv Funct Mater 2014;24:6601-11. [PMID: 25395922 DOI: 10.1002/adfm.201401076] [Cited by in Crossref: 110] [Cited by in F6Publishing: 108] [Article Influence: 13.8] [Reference Citation Analysis]
3 Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29:2357-2363. [PMID: 21519026 DOI: 10.1200/jco2010.33.9473] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Phillips AJ, Lobl MB, Hafeji YA, Safranek HR, Mohr AM, Mott JL. Glycosylation of FGFR4 in cholangiocarcinoma regulates receptor processing and cancer signaling. J Cell Biochem 2022. [PMID: 34981854 DOI: 10.1002/jcb.30204] [Reference Citation Analysis]
5 Zhang B, Zhou BH, Xiao M, Li H, Guo L, Wang MX, Yu SH, Ye QH. KDM5C Represses FASN-Mediated Lipid Metabolism to Exert Tumor Suppressor Activity in Intrahepatic Cholangiocarcinoma. Front Oncol 2020;10:1025. [PMID: 32714863 DOI: 10.3389/fonc.2020.01025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Cho H, Yoo C, Kim KP, Jeong JH, Kang J, Chang HM, Lee SS, Park DH, Song TJ, Lee SK, Kim MH, Lee HC, Lim YS, Kim KM, Shim JH, Hwang S, Song GW, Moon DB, Lee JH, Lee YJ, Ryoo BY. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. Invest New Drugs 2018;36:496-502. [PMID: 29192354 DOI: 10.1007/s10637-017-0548-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang G, Wang Q, Fan X, Ding L, Dong L. The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery. Cancer Manag Res 2019;11:10871-82. [PMID: 31920396 DOI: 10.2147/CMAR.S224583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
8 Carotenuto P, Hedayat S, Fassan M, Cardinale V, Lampis A, Guzzardo V, Vicentini C, Scarpa A, Cascione L, Costantini D, Carpino G, Alvaro D, Ghidini M, Trevisani F, Te Poele R, Salati M, Ventura S, Vlachogiannis G, Hahne JC, Boulter L, Forbes SJ, Guest RV, Cillo U, Said-Huntingford I, Begum R, Smyth E, Michalarea V, Cunningham D, Rimassa L, Santoro A, Roncalli M, Kirkin V, Clarke P, Workman P, Valeri N, Braconi C. Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology 2020;72:982-96. [PMID: 31879968 DOI: 10.1002/hep.31094] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
9 Fragkou N, Sideras L, Panas P, Emmanouilides C, Sinakos E. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence? World J Gastroenterol 2021; 27(27): 4252-4275 [PMID: 34366604 DOI: 10.3748/wjg.v27.i27.4252] [Reference Citation Analysis]
10 Sakamoto T, Honjo S, Morimoto M, Amisaki M, Arai Y, Tokuyasu N, Ashida K, Saito H, Nosaka K, Fujiwara Y. Successful resection of a slow-growing synchronous pulmonary metastasis from distal cholangiocarcinoma resected 3.5 years after initial surgery: a case report. J Med Case Rep 2018;12:136. [PMID: 29784024 DOI: 10.1186/s13256-018-1671-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Rogers JE, Bolonesi RM, Rashid A, Elsayes KM, Elbanan MG, Law L, Kaseb A, Shroff RT. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. J Gastrointest Oncol. 2017;8:347-351. [PMID: 28480073 DOI: 10.21037/jgo.2017.03.03] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
12 Shen WF, Zhong W, Liu Q, Sui CJ, Huang YQ, Yang JM. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg. 2011;35:2083-2091. [PMID: 21698503 DOI: 10.1007/s00268-011-1171-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
13 Limpawattana P, Theerakulpisut D, Wirasorn K, Sookprasert A, Khuntikeo N, Chindaprasirt J. The impact of skeletal muscle mass on survival outcome in biliary tract cancer patients. PLoS One 2018;13:e0204985. [PMID: 30303998 DOI: 10.1371/journal.pone.0204985] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
14 Tanisaka Y, Mizuide M, Fujita A, Ogawa T, Suzuki M, Katsuda H, Saito Y, Miyaguchi K, Tashima T, Mashimo Y, Ryozawa S. Diagnostic Process Using Endoscopy for Biliary Strictures: A Narrative Review. J Clin Med 2021;10:1048. [PMID: 33802525 DOI: 10.3390/jcm10051048] [Reference Citation Analysis]
15 Lertsuwan J, Lertsuwan K, Sawasdichai A, Tasnawijitwong N, Lee KY, Kitchen P, Afford S, Gaston K, Jayaraman PS, Satayavivad J. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers (Basel) 2018;10:E283. [PMID: 30142881 DOI: 10.3390/cancers10090283] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
16 Engel NW, Schliffke S, Schüller U, Frenzel C, Bokemeyer C, Kubisch C, Lessel D. Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin and Gemcitabine in a Patient With Stage IV Cholangiocarcinoma Linked to Post Mortem Diagnosis of Fanconi Anemia. Front Oncol 2019;9:420. [PMID: 31192125 DOI: 10.3389/fonc.2019.00420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Terashima T, Umemoto K, Takahashi H, Hosoi H, Takai E, Kondo S, Sakamoto Y, Mitsunaga S, Ohno I, Hashimoto Y, Sasaki M, Ikeda M, Shimada K, Kaneko S, Yachida S, Sugano K, Okusaka T, Morizane C. Germline mutations in cancer-predisposition genes in patients with biliary tract cancer. Oncotarget 2019;10:5949-57. [PMID: 31666926 DOI: 10.18632/oncotarget.27224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN. Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. Oncotarget 2015;6:23594-608. [PMID: 26090720 DOI: 10.18632/oncotarget.4335] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
19 Li H, Zhang ZY, Zhou ZQ, Guan J, Tong DN, Zhou GW. Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. Oncotarget 2016;7:26888-97. [PMID: 27058753 DOI: 10.18632/oncotarget.8590] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
20 Zhao W, Zhao J, Guo X, Feng Y, Zhang B, Tian L. LncRNA MT1JP plays a protective role in intrahepatic cholangiocarcinoma by regulating miR-18a-5p/FBP1 axis. BMC Cancer 2021;21:142. [PMID: 33557774 DOI: 10.1186/s12885-021-07838-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
21 Massani M, Bonariol L, Stecca T. Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma, a Comprehensive Review. J Clin Med 2021;10:2552. [PMID: 34207700 DOI: 10.3390/jcm10122552] [Reference Citation Analysis]
22 Singh D, Dheer D, Samykutty A, Shankar R. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. J Control Release 2021;340:1-34. [PMID: 34673122 DOI: 10.1016/j.jconrel.2021.10.006] [Reference Citation Analysis]
23 Merla A, Liu KG, Rajdev L. Targeted Therapy in Biliary Tract Cancers. Curr Treat Options Oncol 2015;16:48. [PMID: 26266637 DOI: 10.1007/s11864-015-0366-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
24 Moslim MA, Jeyarajah DR. Narrative review of the role of yttrium-90 selective internal radiation therapy in the surgical management of colorectal liver metastases. J Gastrointest Oncol 2021;12:2438-46. [PMID: 34790404 DOI: 10.21037/jgo-21-96] [Reference Citation Analysis]
25 Shukla HS, Sirohi B, Behari A, Sharma A, Majumdar J, Ganguly M, Tewari M, Kumar S, Saini S, Sahni P, Singh T, Kapoor VK, Sucharita V, Kaur T, Shukla DK, Rath GK. Indian Council of Medical Research consensus document for the management of gall bladder cancer. Indian J Med Paediatr Oncol 2015;36:79-84. [PMID: 26157282 DOI: 10.4103/0971-5851.158829] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
26 Walter D, Döring C, Feldhahn M, Battke F, Hartmann S, Winkelmann R, Schneider M, Bankov K, Schnitzbauer A, Zeuzem S, Hansmann ML, Peveling-Oberhag J. Intratumoral heterogeneity of intrahepatic cholangiocarcinoma. Oncotarget 2017;8:14957-68. [PMID: 28146430 DOI: 10.18632/oncotarget.14844] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
27 Hahn F, Müller L, Mähringer-Kunz A, Schotten S, Düber C, Hinrichs JB, Maschke SK, Galle PR, Bartsch F, Lang H, Weinmann A, Kloeckner R. Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8th edition of the UICC/AJCC Cancer staging system. PLoS One 2020;15:e0228501. [PMID: 32012198 DOI: 10.1371/journal.pone.0228501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 da Costa Miranda V, Braghiroli MI, Faria LD, Siqueira SA, Sabbaga J, Hoff PM, Riechelmann RP. ERCC1 in advanced biliary tract cancer patients treated with chemotherapy: prognostic and predictive roles. J Gastrointest Cancer 2014;45:80-6. [PMID: 24326865 DOI: 10.1007/s12029-013-9568-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
29 Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2012;3:463-9. [PMID: 22969912 DOI: 10.3892/etm.2011.424] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
30 Pollom EL, Alagappan M, Park LS, Whittemore AS, Koong AC, Chang DT. Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Med. 2017;6:129-141. [PMID: 27891822 DOI: 10.1002/cam4.975] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
31 Raevskaya O, Appelman H, Razumilava N. A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma. Curr Hepatol Rep 2020;19:478-85. [PMID: 33415066 DOI: 10.1007/s11901-020-00556-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Takahara N, Nakai Y, Isayama H, Sasaki T, Saito K, Oyama H, Kanai S, Suzuki T, Sato T, Hakuta R, Ishigaki K, Takeda T, Saito T, Mizuno S, Kogure H, Tada M, Koike K. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases. Invest New Drugs 2018;36:1093-102. [PMID: 30324343 DOI: 10.1007/s10637-018-0670-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
33 Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer 2017;116:1402-7. [PMID: 28441383 DOI: 10.1038/bjc.2017.119] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
34 Liu H, Zhang QD, Li ZH, Zhang QQ, Lu LG. Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: A meta-analysis. World J Gastroenterol 2014; 20(47): 18001-18012 [PMID: 25548500 DOI: 10.3748/wjg.v20.i47.18001] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
35 Najran P, Lamarca A, Mullan D, McNamara MG, Westwood T, Hubner RA, Lawrence J, Manoharan P, Bell J, Valle JW. Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. Curr Oncol Rep 2017;19:50. [PMID: 28656502 DOI: 10.1007/s11912-017-0603-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
36 Kim SJ, Jun S, Cho HY, Lee DC, Yeom YI, Kim JH, Kang D. Knockdown of anterior gradient 2 expression extenuates tumor-associated phenotypes of SNU-478 ampulla of Vater cancer cells. BMC Cancer 2014;14:804. [PMID: 25367337 DOI: 10.1186/1471-2407-14-804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
37 Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol 2015;3:169-81. [PMID: 26623263 DOI: 10.14218/JCTH.2015.00012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
38 Köhler M, Harders F, Lohöfer F, Paprottka PM, Schaarschmidt BM, Theysohn J, Herrmann K, Heindel W, Schmidt HH, Pascher A, Stegger L, Rahbar K, Wildgruber M. Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization. J Clin Med 2019;9:E56. [PMID: 31881761 DOI: 10.3390/jcm9010056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
39 Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treat Rev 2020;86:101998. [PMID: 32203843 DOI: 10.1016/j.ctrv.2020.101998] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
40 Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631. [PMID: 21087480 DOI: 10.1186/1471-2407-10-631] [Cited by in Crossref: 110] [Cited by in F6Publishing: 105] [Article Influence: 9.2] [Reference Citation Analysis]
41 Fonkoua LAAK, Mahipal A. Research Progress of Biliary Tract Cancers. Cancers (Basel) 2021;13:919. [PMID: 33671644 DOI: 10.3390/cancers13040919] [Reference Citation Analysis]
42 Yu LH, Yuan B, Fu XH, Yu WL, Liu J, Zhang YJ. Does Anatomic Resection Get More Benefits than Wedge Hepatectomy on the Prognosis for pT3 Unsuspected Gallbladder Cancer?J Laparoendosc Adv Surg Tech A. 2019;29:1414-1418. [PMID: 31403381 DOI: 10.1089/lap.2018.0690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
43 Hong MJ, Cheon YK, Lee EJ, Lee TY, Shim CS. Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma. Gut Liver. 2014;8:318-323. [PMID: 24827630 DOI: 10.5009/gnl.2014.8.3.318] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
44 Molenaar RJ, Coelen RJS, Khurshed M, Roos E, Caan MWA, van Linde ME, Kouwenhoven M, Bramer JAM, Bovée JVMG, Mathôt RA, Klümpen HJ, van Laarhoven HWM, van Noorden CJF, Vandertop WP, Gelderblom H, van Gulik TM, Wilmink JW. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. BMJ Open 2017;7:e014961. [PMID: 28601826 DOI: 10.1136/bmjopen-2016-014961] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
45 Jeong S, Lee K, Wen X, Kim Y, Cho NY, Jang JJ, Kang GH. Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma. BMC Cancer 2017;17:588. [PMID: 28851390 DOI: 10.1186/s12885-017-3595-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
46 Talwar V, Raina S, Goel V, Dash P, Doval DC. Nab-paclitaxel: An effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer. Indian J Med Res 2020;152:475-81. [PMID: 33707389 DOI: 10.4103/ijmr.IJMR_930_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Jarnagin WR. Biliary tract: Is there a role for neoadjuvant and adjuvant therapy in biliary cancer? Nat Rev Gastroenterol Hepatol 2012;9:622-3. [PMID: 23007479 DOI: 10.1038/nrgastro.2012.186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
48 Mosconi C, Solaini L, Vara G, Brandi N, Cappelli A, Modestino F, Cucchetti A, Golfieri R. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis. Cardiovasc Intervent Radiol 2021;44:728-38. [PMID: 33709272 DOI: 10.1007/s00270-021-02800-w] [Reference Citation Analysis]
49 Kim YI, Park JW, Kim BH, Woo SM, Kim TH, Koh YH, Lee WJ, Kim CM. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol. 2013;8:292. [PMID: 24359879 DOI: 10.1186/1748-717x-8-292] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
50 Zhang C, Wang H, Ning Z, Xu L, Zhuang L, Wang P, Meng Z. Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma. Onco Targets Ther 2017;10:1441-9. [PMID: 28331337 DOI: 10.2147/OTT.S124161] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
51 Wu CE, Yeh CN. Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial. Biomolecules 2021;11:1626. [PMID: 34827625 DOI: 10.3390/biom11111626] [Reference Citation Analysis]
52 Patel T. Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8:189-200. [PMID: 21460876 DOI: 10.1038/nrgastro.2011.20] [Cited by in Crossref: 204] [Cited by in F6Publishing: 242] [Article Influence: 18.5] [Reference Citation Analysis]
53 Fiteni F, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M, Dobi E, Fein F, Cleau D, Fratté S, Nerich V, Bonnetain F, Pivot X, Borg C, Kim S. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. BMC Gastroenterol 2014;14:143. [PMID: 25117717 DOI: 10.1186/1471-230X-14-143] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
54 Song SC, Heo JS, Choi DW, Choi SH, Kim WS, Kim MJ. Survival benefits of surgical resection in recurrent cholangiocarcinoma. J Korean Surg Soc 2011;81:187-94. [PMID: 22066120 DOI: 10.4174/jkss.2011.81.3.187] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
55 Naganuma A, Sakuda T, Murakami T, Aihara K, Watanuki Y, Suzuki Y, Shibasaki E, Masuda T, Uehara S, Yasuoka H, Hoshino T, Kudo T, Ishihara H, Ogawa T, Kitamoto Y, Ogawa A. Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab. Intern Med 2020;59:2261-7. [PMID: 32536644 DOI: 10.2169/internalmedicine.4588-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
56 Groot Koerkamp B, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch OR, Coelen RJ, D'Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, Jarnagin WR, van Gulik TM. Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. J Am Coll Surg. 2015;221:1041-1049. [PMID: 26454735 DOI: 10.1016/j.jamcollsurg.2015.09.005] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 10.3] [Reference Citation Analysis]
57 El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ, Blanke CD. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer. 2014;110:882-887. [PMID: 24423918 DOI: 10.1038/bjc.2013.801] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 8.8] [Reference Citation Analysis]
58 Lamarca A, Martinez-Marin V, Feliu J. Cutaneous relapse of an ampullary carcinoma: an unusual presentation. BMJ Case Rep 2012;2012:bcr0120125580. [PMID: 22761197 DOI: 10.1136/bcr.01.2012.5580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
59 Yarlagadda B, Kamatham V, Ritter A, Shahjehan F, Kasi PM. Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma.NPJ Precis Oncol. 2019;3:19. [PMID: 31453370 DOI: 10.1038/s41698-019-0091-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
60 Maynard H, Stadler ZK, Berger MF, Solit DB, Ly M, Lowery MA, Mandelker D, Zhang L, Jordan E, El Dika I, Kemel Y, Ladanyi M, Robson ME, O'Reilly EM, Abou-Alfa GK. Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. Cancer 2020;126:1995-2002. [PMID: 32012241 DOI: 10.1002/cncr.32740] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
61 Noji T, Nagayama M, Imai K, Kawamoto Y, Kuwatani M, Imamura M, Okamura K, Kimura Y, Hirano S. Conversion surgery for initially unresectable biliary malignancies: a multicenter retrospective cohort study. Surg Today 2020;50:1409-17. [PMID: 32468112 DOI: 10.1007/s00595-020-02031-5] [Reference Citation Analysis]
62 Braun S, McSheehy P, Litherland K, McKernan P, Forster-Gross N, Bachmann F, El-Shemerly M, Dimova-Dobreva M, Polyakova I, Häckl M, Zhou P, Lane H, Kellenberger L, Engelhardt M. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma. Expert Opin Investig Drugs 2021;30:1071-80. [PMID: 34698609 DOI: 10.1080/13543784.2021.1995355] [Reference Citation Analysis]
63 LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2013;31:943-948. [PMID: 23263993 DOI: 10.1007/s10637-012-9916-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
64 Beetz O, Klein M, Schrem H, Gwiasda J, Vondran FWR, Oldhafer F, Cammann S, Klempnauer J, Oldhafer KJ, Kleine M. Relevant prognostic factors influencing outcome of patients after surgical resection of distal cholangiocarcinoma. BMC Surg. 2018;18:56. [PMID: 30103720 DOI: 10.1186/s12893-018-0384-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
65 Attia F, Fathy S, Anani M, Hassan A, Attia F, Ibrahim G, Elazab M. Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma. J Clin Lab Anal 2020;34:e23457. [PMID: 32671914 DOI: 10.1002/jcla.23457] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
66 Mayr C, Beyreis M, Wagner A, Pichler M, Neureiter D, Kiesslich T. Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers. Biomed Res Int. 2016;2016:4805270. [PMID: 27957497 DOI: 10.1155/2016/4805270] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
67 Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, El-Haddad G, Biebel B, Parikh N, Arslan B, Hoffe SE, Frakes JM, Springett GM, Anaya DA, Malafa M, Chen DT, Chen Y, Kim RD, Shridhar R, Kis B. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol 2018;29:1101-8. [PMID: 30042074 DOI: 10.1016/j.jvir.2018.04.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
68 Thompson BR, Shi J, Zhu HJ, Smith DE. Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. Biochem Pharmacol 2020;180:114127. [PMID: 32603666 DOI: 10.1016/j.bcp.2020.114127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
69 Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, Hamamoto Y, Ishii H, Boku N, Furuse J. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci 2013;104:1211-6. [PMID: 23763511 DOI: 10.1111/cas.12218] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
70 Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ. A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. Clin Colorectal Cancer 2014;13:81-6. [PMID: 24512954 DOI: 10.1016/j.clcc.2013.12.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
71 Mita K, Ito H, Fukumoto M, Murabayashi R, Nabetani M, Koizumi K, Hayashi T. Gemcitabine and s-1 combination chemotherapy in patients with advanced biliary tract cancer: a retrospective study. Case Rep Oncol 2010;3:498-504. [PMID: 21611105 DOI: 10.1159/000323560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Uwagawa T, Yanaga K. Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. Surg Today 2015;45:1481-8. [PMID: 25673034 DOI: 10.1007/s00595-015-1129-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
73 Sarcognato S, Jong IEM, Fabris L, Cadamuro M, Guido M. Necroptosis in Cholangiocarcinoma. Cells 2020;9:E982. [PMID: 32326539 DOI: 10.3390/cells9040982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
74 He S, Shen J, Sun X, Liu L, Dong J. A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother. 2014;26:243-247. [PMID: 24070164 DOI: 10.1179/1973947813y.0000000133] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
75 Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol. 2014;5:408-413. [PMID: 25436118 DOI: 10.3978/j.issn.2078-6891.2014.072] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
76 Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, Pavelko KD, Li Y, O'Brien D, Wang C, Graham RP, Smoot RL, Dong H, Ilyas S. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest 2020;130:5380-96. [PMID: 32663198 DOI: 10.1172/JCI137110] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 23.0] [Reference Citation Analysis]
77 Vugts JJA, Gaspersz MP, Roos E, Franken LC, Olthof PB, Coelen RJS, van Vugt JLA, Labeur TA, Brouwer L, Besselink MGH, IJzermans JNM, Darwish Murad S, van Gulik TM, de Jonge J, Polak WG, Busch ORC, Erdmann JL, Groot Koerkamp B, Buettner S. Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma.Ann Surg Oncol. 2021;28:1483-1492. [PMID: 32901308 DOI: 10.1245/s10434-020-09001-8] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
78 Sutton TL, Walker BS, Nabavizadeh N, Grossberg A, Thomas CR Jr, Lopez CD, Kardosh A, Chen EY, Sheppard BC, Mayo SC. Geographic Disparities in Referral Rates and Oncologic Outcomes of Intrahepatic Cholangiocarcinoma: A Population-Based Study. Ann Surg Oncol 2021;28:8152-9. [PMID: 34448960 DOI: 10.1245/s10434-021-10650-6] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
79 Sun XF, He ZK, Sun JP, Ge QX, Shen ED. The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis. Oncotarget 2017;8:100657-67. [PMID: 29246010 DOI: 10.18632/oncotarget.20445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
80 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Cited by in Crossref: 473] [Cited by in F6Publishing: 451] [Article Influence: 78.8] [Reference Citation Analysis]
81 Hari DM, Howard JH, Leung AM, Chui CG, Sim MS, Bilchik AJ. A 21-year analysis of stage I gallbladder carcinoma: is cholecystectomy alone adequate? HPB (Oxford). 2013;15:40-48. [PMID: 23216778 DOI: 10.1111/j.1477-2574.2012.00559.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
82 Li Q, Xia X, Ji J, Ma J, Tao L, Mo L, Chen W. MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1. Oncotarget. 2017;8:33621-33630. [PMID: 28422725 DOI: 10.18632/oncotarget.16834] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
83 Koustas E, Trifylli EM, Sarantis P, Papavassiliou AG, Karamouzis MV. Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy. World J Gastrointest Oncol 2021; 13(10): 1229-1243 [PMID: 34721764 DOI: 10.4251/wjgo.v13.i10.1229] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Borad MJ, Gores GJ, Roberts LR. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. Curr Opin Gastroenterol. 2015;31:264-268. [PMID: 25763789 DOI: 10.1097/mog.0000000000000171] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
85 Yamada M, Mizuno T, Yamaguchi J, Yokoyama Y, Igami T, Onoe S, Watanabe N, Uehara K, Matsuo K, Ebata T. Superiority of clinical American Joint Committee on Cancer T classification for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2021. [PMID: 34717042 DOI: 10.1002/jhbp.1066] [Reference Citation Analysis]
86 Leigh N, Solomon D, Pletcher E, Labow DM, Magge DR, Sarpel U, Golas BJ. Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies? World J Surg Oncol 2020;18:124. [PMID: 32527272 DOI: 10.1186/s12957-020-01898-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Titapun A, Techasen A, Sa-Ngiamwibool P, Sithithaworn P, Luvira V, Srisuk T, Jareanrat A, Dokduang H, Loilome W, Thinkhamrop B, Khuntikeo N. Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression. Int J Gen Med 2020;13:1271-83. [PMID: 33273846 DOI: 10.2147/IJGM.S282519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Habermehl D, Brecht IC, Bergmann F, Rieken S, Werner J, Büchler MW, Springfeld C, Jäger D, Debus J, Combs SE. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. World J Surg Oncol 2015;13:149. [PMID: 25889749 DOI: 10.1186/s12957-015-0560-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
89 Popescu I, Dumitrascu T. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg 2014;399:693-705. [PMID: 24841192 DOI: 10.1007/s00423-014-1210-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
90 Halfdanarson TR, Haraldsdottir S, Borad MJ. Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res 2013;2:105. [PMID: 24327864 DOI: 10.12688/f1000research.2-105.v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Engineer R, Patkar S, Lewis SC, Sharma AD, Shetty N, Ostwal V, Ramaswamy A, Chopra S, Agrawal A, Patil P, Mehta S, Goel M. A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol. BMJ Open 2019;9:e028147. [PMID: 31253621 DOI: 10.1136/bmjopen-2018-028147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
92 Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 2015;16:967-978. [PMID: 26179201 DOI: 10.1016/s1470-2045(15)00139-4] [Cited by in Crossref: 133] [Cited by in F6Publishing: 64] [Article Influence: 19.0] [Reference Citation Analysis]
93 Wentrup R, Winkelmann N, Mitroshkin A, Prager M, Voderholzer W, Schachschal G, Jürgensen C, Büning C. Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma. Gut Liver. 2016;10:470-475. [PMID: 26814610 DOI: 10.5009/gnl15175] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
94 Kato S, Fushimi K, Yabuki Y, Maru Y, Hasegawa S, Matsuura T, Kurotaki D, Suzuki A, Kobayashi N, Yoneda M, Higurashi T, Enaka M, Tamura T, Hippo Y, Nakajima A. Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds. Oncogenesis 2021;10:33. [PMID: 33866327 DOI: 10.1038/s41389-021-00322-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
95 Wijetunga I, McVeigh LE, Charalambous A, Antanaviciute A, Carr IM, Nair A, Prasad KR, Ingram N, Coletta PL. Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review. Cancers (Basel) 2020;12:E2817. [PMID: 33007872 DOI: 10.3390/cancers12102817] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Kirkegaard J, Grunnet M, Hasselby JP. A fatal case of primary basaloid squamous cell carcinoma in the intrahepatic bile ducts. Case Rep Pathol 2014;2014:410849. [PMID: 25400964 DOI: 10.1155/2014/410849] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Jones O, Cheng X, Murthy SRK, Ly L, Zhuang T, Basadonna G, Keidar M, Canady J. The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro. Sci Rep 2021;11:8967. [PMID: 33903679 DOI: 10.1038/s41598-021-88451-w] [Reference Citation Analysis]
98 Garcia PL, Miller AL, Gamblin TL, Council LN, Christein JD, Arnoletti JP, Heslin MJ, Reddy S, Richardson JH, Cui X, van Waardenburg RCAM, Bradner JE, Yang ES, Yoon KJ. JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma. Mol Cancer Ther 2018;17:107-18. [PMID: 29142067 DOI: 10.1158/1535-7163.MCT-16-0922] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
99 Graham JS, Boyd K, Coxon FY, Wall LR, Eatock MM, Maughan TS, Highley M, Soulis E, Harden S, Bützberger-Zimmerli P, Evans TR. A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Res Notes 2016;9:161. [PMID: 26969121 DOI: 10.1186/s13104-015-1778-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
100 Takamoto T, Makuuchi M. Precision surgery for primary liver cancer. Cancer Biol Med 2019;16:475-85. [PMID: 31565478 DOI: 10.20892/j.issn.2095-3941.2019.0194] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Taghizadeh H, Müllauer L, Mader R, Prager GW. Applied precision cancer medicine in metastatic biliary tract cancer. Hepatol Int 2020;14:288-95. [PMID: 32100259 DOI: 10.1007/s12072-020-10020-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Thongchot S, Vidoni C, Ferraresi A, Loilome W, Khuntikeo N, Sangkhamanon S, Titapun A, Isidoro C, Namwat N. Cancer-Associated Fibroblast-Derived IL-6 Determines Unfavorable Prognosis in Cholangiocarcinoma by Affecting Autophagy-Associated Chemoresponse. Cancers (Basel) 2021;13:2134. [PMID: 33925189 DOI: 10.3390/cancers13092134] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
103 Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol 2020; 26(25): 3542-3561 [PMID: 32742125 DOI: 10.3748/wjg.v26.i25.3542] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
104 Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99-109. [PMID: 24634588 DOI: 10.2147/clep.s37357clep-6-099] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Tahover E, Bar Shalom R, Bogot N, Kelsen D, Gabizon A. MEK inhibitor treatment is effective in a patient with metastatic carcinoma of the ampulla of Vater with BRAF and NRAS mutations shown by next-generation sequencing. Anticancer Drugs 2016;27:569-72. [PMID: 27075779 DOI: 10.1097/CAD.0000000000000355] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
106 Marciano R, Servetto A, Bianco C, Bianco R. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report. J Med Case Rep 2017;11:273. [PMID: 28946921 DOI: 10.1186/s13256-017-1443-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
107 Noji T, Tsuchikawa T, Mizota T, Okamura K, Nakamura T, Tamoto E, Shichinohe T, Hirano S. Surgery for recurrent biliary carcinoma: results for 27 recurrent cases. World J Surg Oncol 2015;13:82. [PMID: 25884694 DOI: 10.1186/s12957-015-0507-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
108 Lim SM, Yoo JE, Lim KH, Meng Tai DW, Cho BC, Park YN. Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma. Cancer Res Treat 2017;49:185-92. [PMID: 27121721 DOI: 10.4143/crt.2015.497] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
109 Creasy JM, Goldman DA, Gonen M, Dudeja V, Askan G, Basturk O, Balachandran VP, Allen PJ, DeMatteo RP, D'Angelica MI, Jarnagin WR, Peter Kingham T. Predicting Residual Disease in Incidental Gallbladder Cancer: Risk Stratification for Modified Treatment Strategies. J Gastrointest Surg 2017;21:1254-61. [PMID: 28484891 DOI: 10.1007/s11605-017-3436-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
110 Kamposioras K, Geraghty J, Appleyard J, Dawod M, Papadimitriou K, Lamarca A, Anthoney A. Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies. J Gastrointest Cancer 2021. [PMID: 34648136 DOI: 10.1007/s12029-021-00718-7] [Reference Citation Analysis]
111 Yuan X, Li J, Coulouarn C, Lin T, Sulpice L, Bergeat D, De La Torre C, Liebe R, Gretz N, Ebert MPA, Dooley S, Weng HL. SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance. Br J Cancer 2018;119:1358-66. [PMID: 30420613 DOI: 10.1038/s41416-018-0338-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
112 Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, Folseraas T, Fabris L, Macias RIR, Krawczyk M, Krawczyk M, Cardinale V, Braconi C, Alvaro D, Evert M, Banales JM, Valle JW; Group: on behalf of the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology 2021;73:2311-25. [PMID: 33073396 DOI: 10.1002/hep.31598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
113 Erice O, Vallejo A, Ponz-Sarvise M, Saborowski M, Vogel A, Calvisi DF, Saborowski A, Vicent S. Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research. Cancers (Basel) 2019;11:E1868. [PMID: 31769429 DOI: 10.3390/cancers11121868] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
114 Suksawat M, Klanrit P, Phetcharaburanin J, Namwat N, Khuntikeo N, Titapun A, Jarearnrat A, Sa-Ngiamwibool P, Techasen A, Loilome W. In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues. PLoS One 2019;14:e0222140. [PMID: 31504065 DOI: 10.1371/journal.pone.0222140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
115 Hong Y, Li X, Cao D. Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification. Front Oncol 2021;11:538328. [PMID: 33763343 DOI: 10.3389/fonc.2021.538328] [Reference Citation Analysis]
116 Peng T, Deng X, Tian F, Li Z, Jiang P, Zhao X, Chen G, Chen Y, Zheng P, Li D, Wang S. The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma. Int J Oncol 2019;55:657-70. [PMID: 31322171 DOI: 10.3892/ijo.2019.4837] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
117 Arrington AK, Nelson RA, Falor A, Luu C, Wiatrek RL, Fakih M, Singh G, Kim J. Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. World J Gastrointest Surg 2013; 5(6): 178-186 [PMID: 23977420 DOI: 10.4240/wjgs.v5.i6.178] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
118 Bin Waqar SH, Salahi N, Zhonghua L, McFarlane IM. Advanced Squamous Cell Carcinoma of Gall Bladder Masquerading as Liver Abscess With Review of Literature Review on Advanced Biliary Tract Cancer. Cureus 2021;13:e16867. [PMID: 34513442 DOI: 10.7759/cureus.16867] [Reference Citation Analysis]
119 Kim KP, Jang G, Hong YS, Lim HS, Bae KS, Kim HS, Lee SS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br J Cancer 2011;104:605-12. [PMID: 21326246 DOI: 10.1038/bjc.2011.17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
120 Rexha I, Laage-Gaupp F, Chapiro J, Miszczuk MA, van Breugel JMM, Lin M, Konstantinidis M, Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma. Sci Rep 2021;11:9337. [PMID: 33927226 DOI: 10.1038/s41598-021-88426-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Luo Y, Li JL, Yang L, Zhang W. Chemotherapy with gemcitabine plus cisplatin in patients with advanced thymic squamous cell carcinoma: Evaluation of efficacy and toxicity. Thorac Cancer 2016;7:167-72. [PMID: 27042218 DOI: 10.1111/1759-7714.12300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
122 Takahari D, Shinozaki E, Wakatsuki T, Ooki A, Ozaka M, Suzuki T, Nakayama I, Osumi H, Kamiimabeppu D, Sato T, Ogura M, Suenaga M, Chin K, Yamaguchi K. Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research. Int J Clin Oncol 2021;26:335-44. [PMID: 33085057 DOI: 10.1007/s10147-020-01806-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
123 Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, Phelps MA, Villalona-Calero MA, Bekaii-Saab T. Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Sci Rep 2015;5:12122. [PMID: 26161813 DOI: 10.1038/srep12122] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
124 Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015;20:1019-1027. [PMID: 26245674 DOI: 10.1634/theoncologist.2015-0210] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
125 Lin J, Yang X, Long J, Zhao S, Mao J, Wang D, Bai Y, Bian J, Zhang L, Yang X, Wang A, Xie F, Shi W, Yang H, Pan J, Hu K, Guan M, Zhao L, Huo L, Mao Y, Sang X, Wang K, Zhao H. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 2020;9:414-24. [PMID: 32832493 DOI: 10.21037/hbsn-20-338] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
126 Thuehøj AU, Andersen NC, Worm ES, Høyer M, Tabaksblat EM, Weber B, Mortensen HR. Clinical outcomes after stereotactic ablative radiotherapy in locally advanced cholangiocarcinoma. Acta Oncol 2021;:1-5. [PMID: 34726565 DOI: 10.1080/0284186X.2021.1995893] [Reference Citation Analysis]
127 Qadan M, Kingham TP. Technical Aspects of Gallbladder Cancer Surgery. Surg Clin North Am 2016;96:229-45. [PMID: 27017862 DOI: 10.1016/j.suc.2015.12.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
128 Lee SH, Kim JM, Lee DG, Lee J, Park JG, Han TS, Cho HS, Cho YL, Bae KH, Park YJ, Lee SJ, Lee MS, Huh YM, Jo DY, Yun HJ, Jeon HJ, Kim N, Joo M, Kim JS, Lee HJ, Min JK. Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation. Cell Death Differ 2021;28:968-84. [PMID: 32989241 DOI: 10.1038/s41418-020-00628-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
129 Cherkassky L, Jarnagin W. Selecting treatment sequence for patients with incidental gallbladder cancer: a neoadjuvant approach versus upfront surgery. Updates Surg 2019;71:217-25. [PMID: 31254234 DOI: 10.1007/s13304-019-00670-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
130 Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev. 2018;4:CD011746. [PMID: 29624208 DOI: 10.1002/14651858.cd011746.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
131 Zhang Z, Zhang W, Wang H, Hu B, Wang Z, Lu S. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report. Front Immunol 2021;12:744571. [PMID: 34603331 DOI: 10.3389/fimmu.2021.744571] [Reference Citation Analysis]
132 Wehrkamp CJ, Gutwein AR, Natarajan SK, Phillippi MA, Mott JL. XIAP antagonist embelin inhibited proliferation of cholangiocarcinoma cells. PLoS One 2014;9:e90238. [PMID: 24603802 DOI: 10.1371/journal.pone.0090238] [Cited by in Crossref: 8] [Cited by in F6Publishing: 55] [Article Influence: 1.0] [Reference Citation Analysis]
133 Macias RI. Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. ISRN Hepatol 2014;2014:828074. [PMID: 27335842 DOI: 10.1155/2014/828074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
134 Sakamoto T, Kobayashi S, Yamada D, Nagano H, Tomokuni A, Tomimaru Y, Noda T, Gotoh K, Asaoka T, Wada H, Kawamoto K, Marubashi S, Eguchi H, Doki Y, Mori M. A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer. PLoS One 2016;11:e0145985. [PMID: 26726879 DOI: 10.1371/journal.pone.0145985] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
135 Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016;35:263-275. [PMID: 26857926 DOI: 10.1007/s10555-016-9602-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
136 Yu Y, Huang S, Chen J, Yu F, Zhang L, Xiang X, Deng J, Fang Z, Li J, Xiong J. An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers. Cancer Control 2021;28:10732748211017165. [PMID: 33982628 DOI: 10.1177/10732748211017165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Spratlin JL, Chu Q, Koski S, King K, Mulder K. Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol 2011; 2(3): 135-149 [PMID: 21611088 DOI: 10.5306/wjco.v2.i3.135] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
138 Desai AM, Lichtman SM. Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biol Med. 2015;12:284-291. [PMID: 26779365 DOI: 10.7497/j.issn.2095-3941.2015.0078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Servajean C, Gilabert M, Piana G, Monges G, Delpero JR, Brenot I, Raoul JL. One case of intrahepatic cholangiocarcinoma amenable to resection after radioembolization. World J Gastroenterol 2014; 20(17): 5131-5134 [PMID: 24803830 DOI: 10.3748/wjg.v20.i17.5131] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
140 Friend E, Yadegarfar G, Byrne C, Johnson CD, Sezer O, Pucciarelli S, Pereira SP, Chie WC, Banfield A, Ramage JK; EORTC Quality of Life Group. Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. Br J Cancer 2011;104:587-92. [PMID: 21266979 DOI: 10.1038/sj.bjc.6606086] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
141 Takada N, Sugano H, Shirai Y, Saito N, Hamura R, Taniai T, Uwagawa T, Yanaga K, Ikegami T, Ohashi T, Eto K. Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells. PLoS One 2021;16:e0257019. [PMID: 34473771 DOI: 10.1371/journal.pone.0257019] [Reference Citation Analysis]
142 Zimmer V, Höblinger A, Mihalache F, Assmann G, Acalovschi M, Lammert F. Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility. Oncol Lett 2012;4:101-6. [PMID: 22807971 DOI: 10.3892/ol.2012.680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
143 Leng K, Xu Y, Kang P, Qin W, Cai H, Wang H, Ji D, Jiang X, Li J, Li Z, Huang L, Zhong X, Sun X, Wang Z, Cui Y. Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6/STAT3/VEGFA signaling pathway. Cell Death Dis 2019;10:262. [PMID: 30886152 DOI: 10.1038/s41419-019-1506-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
144 Das S, Berlin J. Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. Surg Oncol Clin N Am 2021;30:189-204. [PMID: 33220805 DOI: 10.1016/j.soc.2020.08.008] [Reference Citation Analysis]
145 Agarwal R, Sendilnathan A, Siddiqi NI, Gulati S, Ghose A, Xie C, Olowokure OO. Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States. J Gastrointest Oncol 2016;7:996-1003. [PMID: 28078124 DOI: 10.21037/jgo.2016.09.10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
146 Monsereenusorn C, Satayasoontorn K, Rujkijyanont P, Traivaree C. Cholangiocarcinoma in a Child with Progressive Abdominal Distension and Secondary Hypercalcemia. Case Rep Pediatr 2018;2018:6828037. [PMID: 29850347 DOI: 10.1155/2018/6828037] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Tsukagoshi M, Araki K, Yokobori T, Altan B, Suzuki H, Kubo N, Watanabe A, Ishii N, Hosouchi Y, Nishiyama M, Shirabe K, Kuwano H. Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins. Oncotarget 2017;8:42159-72. [PMID: 28178675 DOI: 10.18632/oncotarget.15020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
148 Fraveto A, Cardinale V, Bragazzi MC, Giuliante F, De Rose AM, Grazi GL, Napoletano C, Semeraro R, Lustri AM, Costantini D, Nevi L, Di Matteo S, Renzi A, Carpino G, Gaudio E, Alvaro D. Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. PLoS One. 2015;10:e0142124. [PMID: 26571380 DOI: 10.1371/journal.pone.0142124] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
149 Miyata T, Okabe H, Chikamoto A, Yamao T, Umezaki N, Tsukamoto M, Kitano Y, Arima K, Nakagawa S, Imai K, Hashimoto D, Yamashita YI, Baba H. A long-term survivor of hilar cholangiocarcinoma with resection of recurrent peritoneal dissemination after R0 surgery: a case report. Surg Case Rep 2017;3:110. [PMID: 29039079 DOI: 10.1186/s40792-017-0386-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
150 Tantau AI, Mandrutiu A, Pop A, Zaharie RD, Crisan D, Preda CM, Tantau M, Mercea V. Extrahepatic cholangiocarcinoma: Current status of endoscopic approach and additional therapies. World J Hepatol 2021; 13(2): 166-186 [PMID: 33708349 DOI: 10.4254/wjh.v13.i2.166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
151 Jiang Y, Zeng Z, Zeng J, Liu C, Qiu J, Li Y, Tang J, Mo N, Du L, Ma J. Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:736113. [PMID: 34650920 DOI: 10.3389/fonc.2021.736113] [Reference Citation Analysis]
152 Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013;32:4861-4870. [PMID: 23318457 DOI: 10.1038/onc.2012.617] [Cited by in Crossref: 140] [Cited by in F6Publishing: 135] [Article Influence: 15.6] [Reference Citation Analysis]
153 Cheng Y, Zhang J, Qin SK, Hua HQ. Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report. Onco Targets Ther 2018;11:5957-62. [PMID: 30271179 DOI: 10.2147/OTT.S176914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Spolverato G, Bagante F, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Winslow E, Cho C, Martin RC, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Maithel SK, Pawlik TM. Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. World J Surg 2017;41:224-31. [PMID: 27549595 DOI: 10.1007/s00268-016-3691-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
155 Peng DZ, Lu J, Li B, Hu HJ, Ye XW, Xiong XZ, Cheng NS. A simple scoring system to predict early recurrence of Bismuth-Corlette type IV perihilar cholangiocarcinoma. Gastroenterol Rep (Oxf) 2019;7:345-53. [PMID: 31687154 DOI: 10.1093/gastro/goz012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
156 Sangkhamanon S, Jongpairat P, Sookprasert A, Wirasorn K, Titapun A, Pugkhem A, Ungareevittaya P, Chindaprasirt J. Programmed Death-Ligand 1 (PD-L1) Expression Associated with a High Neutrophil/Lymphocyte Ratio in Cholangiocarcinoma. Asian Pac J Cancer Prev 2017;18:1671-4. [PMID: 28670887 DOI: 10.22034/APJCP.2017.18.6.1671] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
157 Lee TY, Bates SE, Abou-Alfa GK. Equipoise, drug development, and biliary cancer. Cancer 2021. [PMID: 34817855 DOI: 10.1002/cncr.34020] [Reference Citation Analysis]
158 Yang B, Tong R, Liu H, Wu J, Chen D, Xue Z, Ding C, Zhou L, Xie H, Wu J, Zheng S. H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma. Int J Oncol 2018;52:1235-45. [PMID: 29532867 DOI: 10.3892/ijo.2018.4292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
159 Sasaki R, Ohya Y, Hayashida S, Maeda Y, Murahashi S, Kumamoto S, Tsuji A, Shibata H, Kuramoto K, Hayashi H, Kuriwaki K, Iizaka M, Nakahara O, Inomata Y. A case of Trousseau's syndrome due to intrahepatic cholangiocarcinoma with an extremely high level of CA19-9. Surg Case Rep 2020;6:75. [PMID: 32307602 DOI: 10.1186/s40792-020-00835-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
160 Lau DK, Tay RY, Yeung YH, Chionh F, Mooi J, Murone C, Skrinos E, Price TJ, Mariadason JM, Tebbutt NC. Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. Br J Cancer 2018;118:966-71. [PMID: 29527009 DOI: 10.1038/s41416-018-0021-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
161 Go SI, Kim YS, Hwang IG, Kim EY, Oh SY, Ji JH, Song HN, Park SH, Park JO, Kang JH. Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis. Cancer Res Treat 2016;48:1274-85. [PMID: 26875193 DOI: 10.4143/crt.2015.502] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
162 Al-Shamsi HO, Anand D, Shroff RT, Jain A, Zuo M, Conrad C, Vauthey JN, Javle MM. BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype. J Gastrointest Oncol 2016;7:556-61. [PMID: 27563445 DOI: 10.21037/jgo.2016.03.05] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
163 Lischalk JW, Repka MC, Unger K. Radiation therapy for hepatobiliary malignancies. J Gastrointest Oncol. 2017;8:279-292. [PMID: 28480067 DOI: 10.21037/jgo.2016.08.02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
164 Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28:3531-3540. [PMID: 20547994 DOI: 10.1200/jco.2009.27.4787] [Cited by in Crossref: 139] [Cited by in F6Publishing: 87] [Article Influence: 11.6] [Reference Citation Analysis]
165 Jeong H, Jeong JH, Kim KP, Lee SS, Oh DW, Park DH, Song TJ, Park Y, Hong SM, Ryoo BY, Yoo C. Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin. Cancers (Basel) 2021;13:E161. [PMID: 33418871 DOI: 10.3390/cancers13020161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Kim GH, Kim PH, Kim JH, Kim PN, Won HJ, Shin YM, Choi SH. Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Eur Radiol 2021. [PMID: 34347159 DOI: 10.1007/s00330-021-08216-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Sumiyoshi T, Shima Y, Okabayashi T, Negoro Y, Shimada Y, Iwata J, Matsumoto M, Hata Y, Noda Y, Sui K, Sueda T. Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma. World J Surg. 2018;42:2910-2918. [PMID: 29511872 DOI: 10.1007/s00268-018-4558-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
168 Lee PC, Hendifar A, Osipov A, Cho M, Li D, Gong J. Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations. Cancers (Basel) 2021;13:1706. [PMID: 33916849 DOI: 10.3390/cancers13071706] [Reference Citation Analysis]
169 Li Z, Liu J, Chen T, Sun R, Liu Z, Qiu B, Xu Y, Zhang Z. HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc. J Exp Clin Cancer Res 2021;40:86. [PMID: 33648560 DOI: 10.1186/s13046-021-01890-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
170 Wu CE, Pan YR, Yeh CN, Lunec J. Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers. Biomolecules 2020;10:E1474. [PMID: 33113997 DOI: 10.3390/biom10111474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
171 Han Y, Zhang H, Zhou Z, Liu R, Liu D, Bai M, Fan Q, Li J, Zhu K, Li H, Ning T, Ying G, Ba Y. Serum microRNAs as Biomarkers for the Noninvasive Early Diagnosis of Biliary Tract Cancer. Int J Gen Med 2021;14:1185-95. [PMID: 33833559 DOI: 10.2147/IJGM.S297371] [Reference Citation Analysis]
172 Cousin S, Cantarel C, Guegan JP, Mazard T, Gomez-Roca C, Metges JP, Bellera C, Adenis A, Korakis I, Poureau PG, Bourcier K, Toulmonde M, Kind M, Rey C, Auzanneau C, Bessede A, Soubeyran I, Italiano A. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur J Cancer 2022;162:161-9. [PMID: 34998048 DOI: 10.1016/j.ejca.2021.11.012] [Reference Citation Analysis]
173 Oh MY, Kim H, Choi YJ, Byun Y, Han Y, Kang JS, Sohn H, Lee JM, Kwon W, Jang JY. Conversion surgery for initially unresectable extrahepatic biliary tract cancer. Ann Hepatobiliary Pancreat Surg 2021;25:349-57. [PMID: 34402435 DOI: 10.14701/ahbps.2021.25.3.349] [Reference Citation Analysis]
174 Squires MH, Woelfel I, Cloyd JM, Pawlik TM. Emerging treatment options for cholangiocarcinoma. Expert Opinion on Orphan Drugs 2018;6:527-36. [DOI: 10.1080/21678707.2018.1476235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Wu T, Jiang X, Xu B, Wang Y. [Ponatinib inhibits growth of patient-derived xenograft of cholangiocarcinoma expressing FGFR2-CCDC6 fusion protein in nude mice]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:1448-56. [PMID: 33118510 DOI: 10.12122/j.issn.1673-4254.2020.10.10] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
176 Bednarsch J, Czigany Z, Heij LR, Liu D, den Dulk M, Wiltberger G, Bruners P, Ulmer TF, Neumann UP, Lang SA. Compelling Long-Term Results for Liver Resection in Early Cholangiocarcinoma. J Clin Med 2021;10:2959. [PMID: 34209368 DOI: 10.3390/jcm10132959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Cetin R, Quandt E, Kaulich M. Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance. Cells 2021;10:260. [PMID: 33525637 DOI: 10.3390/cells10020260] [Reference Citation Analysis]
178 Han S, Lee SY, Wang WW, Tan YB, Sim RHZ, Cheong R, Tan C, Hopkins R, Connolly J, Shuen WH, Toh HC. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers (Basel) 2020;12:E3404. [PMID: 33212880 DOI: 10.3390/cancers12113404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
179 Chen C, Nelson LJ, Ávila MA, Cubero FJ. Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link. Cells 2019;8:E1172. [PMID: 31569444 DOI: 10.3390/cells8101172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
180 Zlobec I, Berger MD, Lugli A. Tumour budding and its clinical implications in gastrointestinal cancers. Br J Cancer 2020;123:700-8. [PMID: 32601463 DOI: 10.1038/s41416-020-0954-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
181 Wiesweg M, Aydin S, Koeninger A, Stein A, Schara U, van Roye C, Hense J, Welt A, Schuler M. Administration of Gemcitabine for Metastatic Adenocarcinoma during Pregnancy: A Case Report and Review of the Literature. AJP Rep 2014;4:17-22. [PMID: 25032054 DOI: 10.1055/s-0034-1368091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
182 Okusaka T. Cholangiocarcinoma: is it time for a revolution? Expert Rev Gastroenterol Hepatol 2021;15:467-70. [PMID: 33840344 DOI: 10.1080/17474124.2021.1915766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
184 Klöckl MC, Kasparek AK, Riedl JM, Moik F, Mollnar S, Stotz M, Szkandera J, Terbuch A, Gerger A, Niedrist T, Pichler M, Bauernhofer T, Schilcher G, Zitta S, Rosenkranz AR, Friedl C, Stöger H, Posch F. Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy. Sci Rep 2020;10:11219. [PMID: 32641710 DOI: 10.1038/s41598-020-68010-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Albrecht T, Brinkmann F, Albrecht M, Lonsdorf AS, Mehrabi A, Hoffmann K, Kulu Y, Charbel A, Vogel MN, Rupp C, Köhler B, Springfeld C, Schirmacher P, Roessler S, Goeppert B. Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer. Cancers (Basel) 2021;13:1682. [PMID: 33918309 DOI: 10.3390/cancers13071682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Horgan A, Knox J, Aneja P, Le L, McKeever E, McNamara M. Patterns of care and treatment outcomes in older patients with biliary tract cancer. Oncotarget 2015;6:44995-5004. [PMID: 26575326 DOI: 10.18632/oncotarget.5707] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
187 El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012;30:1646-1651. [PMID: 21748296 DOI: 10.1007/s10637-011-9719-0] [Cited by in Crossref: 101] [Cited by in F6Publishing: 97] [Article Influence: 9.2] [Reference Citation Analysis]
188 De B, Abu-Gheida I, Patel A, Ng SSW, Zaid M, Thunshelle CP, Elganainy D, Corrigan KL, Rooney MK, Javle M, Raghav K, Lee SS, Vauthey JN, Tzeng CD, Tran Cao HS, Ludmir EB, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Koay EJ. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med 2021;11:1270. [PMID: 34945742 DOI: 10.3390/jpm11121270] [Reference Citation Analysis]
189 Tajima H, Ohta T, Shinbashi H, Hirose A, Okazaki M, Yamaguchi T, Ohbatake Y, Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Miyashita T, Takamura H, Ninomiya I, Fushida S, Nakamura H. Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer. Mol Clin Oncol 2017;6:753-7. [PMID: 28529750 DOI: 10.3892/mco.2017.1206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
190 Kim E, Kim YJ, Kim K, Song C, Kim JS, Oh DY, Nam EM, Chie EK. Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery. Br J Radiol 2017;90:20170308. [PMID: 28937265 DOI: 10.1259/bjr.20170308] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
191 Ikeda Y, Ono M, Ohmori G, Ameda S, Yamada M, Abe T, Fujii S, Fujita M, Maeda M. Successful pembrolizumab treatment of microsatellite instability-high intrahepatic cholangiocarcinoma: A case report. Clin Case Rep 2021;9:2259-63. [PMID: 33936676 DOI: 10.1002/ccr3.4008] [Reference Citation Analysis]
192 Sahu R, Sharma P, Kumar A. An Insight into Cholangiocarcinoma and Recent Advances in its Treatment. J Gastrointest Cancer 2022. [PMID: 35023010 DOI: 10.1007/s12029-021-00728-5] [Reference Citation Analysis]
193 Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72-79. [PMID: 22180306 DOI: 10.1634/theoncologist.2011-0386] [Cited by in Crossref: 446] [Cited by in F6Publishing: 475] [Article Influence: 40.5] [Reference Citation Analysis]
194 Alshari OM, Dawaymeh TA, Tashtush NA, Aleshawi AJ, Al Manasra ARA, Obeidat KA. Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases. Onco Targets Ther 2019;12:5293-8. [PMID: 31308699 DOI: 10.2147/OTT.S197559] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
195 Nakashima S, Kobayashi S, Nagano H, Tomokuni A, Tomimaru Y, Asaoka T, Hama N, Wada H, Kawamoto K, Marubashi S. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. Cancer Sci. 2015;106:584-591. [PMID: 25736055 DOI: 10.1111/cas.12652] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
196 Rizzo A, Ricci AD, Tavolari S, Brandi G. Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. Cancer Genomics Proteomics. 2020;17:441-452. [PMID: 32859625 DOI: 10.21873/cgp.20203] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 38.0] [Reference Citation Analysis]
197 Chakrabarti S, Kamgar M, Mahipal A. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.Cancers (Basel). 2020;12. [PMID: 32722188 DOI: 10.3390/cancers12082039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
198 Zarei M, Hue JJ, Hajihassani O, Graor HJ, Katayama ES, Loftus AW, Bajor D, Rothermel LD, Vaziri-Gohar A, Winter JM. Clinical development of IDH1 inhibitors for cancer therapy. Cancer Treat Rev 2021;103:102334. [PMID: 34974243 DOI: 10.1016/j.ctrv.2021.102334] [Reference Citation Analysis]
199 Kamphues C, Seehofer D, Collettini F, Bahra M, Neuhaus P, Wust P, Denecke T, Gebauer B, Schnapauff D. Preliminary experience with CT-guided high-dose rate brachytherapy as an alternative treatment for hepatic recurrence of cholangiocarcinoma. HPB (Oxford) 2012;14:791-7. [PMID: 23134179 DOI: 10.1111/j.1477-2574.2012.00537.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
200 Imperatori M, D'Onofrio L, Marrucci E, Pantano F, Zoccoli A, Tonini G. Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives. Hepat Oncol 2016;3:93-9. [PMID: 30191029 DOI: 10.2217/hep.15.43] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
201 Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol 2021;5:PO. [PMID: 34778691 DOI: 10.1200/PO.21.00064] [Reference Citation Analysis]
202 Bateni SB, Gingrich AA, Kirane AR, Sauder CAM, Gholami S, Bold RJ, Meyers FJ, Canter RJ. Chemotherapy After Diagnosis of Malignant Bowel Obstruction is Associated with Superior Survival for Medicare Patients with Advanced Malignancy. Ann Surg Oncol 2021. [PMID: 33829359 DOI: 10.1245/s10434-021-09831-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
203 Jung DE, Park SB, Kim K, Kim C, Song SY. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway. Sci Rep 2017;7:10921. [PMID: 28883618 DOI: 10.1038/s41598-017-11094-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
204 Muramatsu M, Tsuchiya A, Ohta S, Iijima Y, Maruyama M, Onodera Y, Hagihara M, Nakaya N, Sato I, Omura K, Ueno S, Nakajima H. Measuring body composition using the bioelectrical impedance method can predict the outcomes of gemcitabine-based chemotherapy in patients with pancreatobiliary tract cancer. Oncol Lett 2015;10:3535-41. [PMID: 26788165 DOI: 10.3892/ol.2015.3811] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
205 Narang AK, Miller RC, Hsu CC, Bhatia S, Pawlik TM, Laheru D, Hruban RH, Zhou J, Winter JM, Haddock MG. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol. 2011;6:126. [PMID: 21951377 DOI: 10.1186/1748-717x-6-126] [Cited by in Crossref: 73] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
206 Baichan P, Naicker P, Devar JWS, Smith M, Candy GP, Nweke E. Targeting gallbladder cancer: a pathway based perspective. Mol Biol Rep 2020;47:2361-9. [PMID: 32020429 DOI: 10.1007/s11033-020-05269-x] [Reference Citation Analysis]
207 Zhang R, Puzzoni M, Mariani S, Zheng Y, Liscia N, Guo Y, Donisi C, Liu Y, Impera V, Fang W, Scartozzi M. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Sci 2021. [PMID: 34534382 DOI: 10.1111/cas.15139] [Reference Citation Analysis]
208 Kim BH, Chie EK, Kim K, Jang JY, Kim SW, Oh DY, Bang YJ, Ha SW. Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution. Oncotarget 2017;8:78076-85. [PMID: 29100449 DOI: 10.18632/oncotarget.17368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
209 Plis A, Zygulska A, Püsküllüoğlu M, Szczepański W, Białas M, Krupiński M, Krzemieniecki K. Synchronous extraskeletal Ewing's sarcoma/PNET and gallbladder carcinoma: a case report and literature review. Contemp Oncol (Pozn) 2016;20:496-500. [PMID: 28239290 DOI: 10.5114/wo.2016.65612] [Reference Citation Analysis]
210 Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Uson PLS, Nagalo BM, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemother Pharmacol 2020;85:1063-78. [PMID: 32440762 DOI: 10.1007/s00280-020-04079-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
211 Nagino M. Perihilar cholangiocarcinoma: a surgeon’s viewpoint on current topics. J Gastroenterol. 2012;47:1165-1176. [PMID: 22847554 DOI: 10.1007/s00535-012-0628-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
212 Sato S, Chinda D, Tanaka Y, Kaizuka N, Higuchi N, Ota S, Miyazawa K, Kikuchi H, Aizawa S, Iwamura H, Fukuda S. Effective Endoscopic Closure of Cholecysto-duodenal and Transverse Colon Fistulas Due to Squamous Cell Carcinoma of the Gallbladder Using Polyglycolic Acid Sheets and a Covered Metal Stent. Intern Med 2021;60:1723-9. [PMID: 33390496 DOI: 10.2169/internalmedicine.6384-20] [Reference Citation Analysis]
213 Panettieri E, Maki H, Kim BJ, Kang HC, Cox V, Vega EA, Mizuno T, Pant S, Javle M, Vauthey JN, Kawaguchi Y. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. Surg Oncol 2021;40:101696. [PMID: 34995974 DOI: 10.1016/j.suronc.2021.101696] [Reference Citation Analysis]
214 Bi J, Ma H, Liu Y, Huang A, Xiao Y, Shu WJ, Du H, Zhang T. Upregulation of PAIP1 promotes the gallbladder tumorigenesis through regulating PLK1 level. Ann Transl Med 2021;9:991. [PMID: 34277791 DOI: 10.21037/atm-21-2417] [Reference Citation Analysis]
215 Namjan A, Techasen A, Loilome W, Sa-Ngaimwibool P, Jusakul A. ARID1A alterations and their clinical significance in cholangiocarcinoma. PeerJ 2020;8:e10464. [PMID: 33344089 DOI: 10.7717/peerj.10464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
216 Turgeon MK, Maithel SK. Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy. Chin Clin Oncol 2020;9:4. [PMID: 31500433 DOI: 10.21037/cco.2019.08.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
217 Qin BD, Jiao XD, Liu K, Wu Y, He X, Liu J, Qin WX, Wang Z, Zang YS. Basket Trials for Intractable Cancer. Front Oncol 2019;9:229. [PMID: 31032221 DOI: 10.3389/fonc.2019.00229] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
218 Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RL, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discov 2016;6:727-39. [PMID: 27231123 DOI: 10.1158/2159-8290.CD-15-1442] [Cited by in Crossref: 75] [Cited by in F6Publishing: 56] [Article Influence: 12.5] [Reference Citation Analysis]
219 Duffy AG, Makarova-Rusher OV, Greten TF. The case for immune-based approaches in biliary tract carcinoma. Hepatology 2016;64:1785-91. [PMID: 27177447 DOI: 10.1002/hep.28635] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
220 Sharma MR, Schilsky RL. GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy. Nat Rev Clin Oncol 2011;8:70-2. [PMID: 21278772 DOI: 10.1038/nrclinonc.2010.219] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
221 Xu S, Zhan M, Jiang C, He M, Yang L, Shen H, Huang S, Huang X, Lin R, Shi Y, Liu Q, Chen W, Mohan M, Wang J. Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. Nat Commun 2019;10:5492. [PMID: 31792210 DOI: 10.1038/s41467-019-13420-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
222 Pan R, Yuan Z, Liu Y, Sun X, Wang G, Wang X, Qu J, Wang J, Yang J, Zhao Y, Yang Y, Li K. A redox probe screens MTHFD1 as a determinant of gemcitabine chemoresistance in cholangiocarcinoma. Cell Death Discov 2021;7:89. [PMID: 33934113 DOI: 10.1038/s41420-021-00476-2] [Reference Citation Analysis]
223 Ostwal V, Swami R, Patkar S, Majumdar S, Goel M, Mehta S, Engineer R, Mandavkar S, Kumar S, Ramaswamy A. Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward. Med Oncol 2018;35:57. [PMID: 29564657 DOI: 10.1007/s12032-018-1115-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
224 Konstantinidis IT, Do RK, Gultekin DH, Gönen M, Schwartz LH, Fong Y, Allen PJ, D’Angelica MI, DeMatteo RP, Klimstra DS. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol. 2014;21:2675-2683. [PMID: 24664624 DOI: 10.1245/s10434-014-3649-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
225 Okubo S, Nishiuma S, Kobayashi N, Taketsuna M, Taniai H. Safety and effectiveness of gemcitabine in 260 patients with biliary tract cancer in a Japanese clinical practice based on post-marketing surveillance in Japan. Jpn J Clin Oncol 2012;42:1043-53. [PMID: 23042772 DOI: 10.1093/jjco/hys149] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
226 Simone V, Brunetti O, Lupo L, Testini M, Maiorano E, Simone M, Longo V, Rolfo C, Peeters M, Scarpa A, Azzariti A, Russo A, Ribatti D, Silvestris N. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. Int J Mol Sci 2017;18:E418. [PMID: 28212293 DOI: 10.3390/ijms18020418] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
227 Sun D, Ma J, Wang J, Han C, Qian Y, Chen G, Li X, Zhang J, Cui P, Du W, Wu Z, Chen S, Zheng X, Yue Z, Song J, Gao C, Zhao X, Cai S, Hu Y. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunol Immunother 2019;68:1527-35. [PMID: 31535160 DOI: 10.1007/s00262-019-02386-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
228 Zheng Y, Tu X, Zhao P, Jiang W, Liu L, Tong Z, Zhang H, Yan C, Fang W, Wang W. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer 2018;119:291-5. [PMID: 29955136 DOI: 10.1038/s41416-018-0138-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
229 Jiang ZQ, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, Shroff R, Katz M, Wolff RA, Fleming J. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 2013;24:2349-2353. [PMID: 23704197 DOI: 10.1093/annonc/mdt191] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
230 Patel A, Sirohi B. Nab-paclitaxel - Third-line chemotherapy in advanced gallbladder cancer. Indian J Med Res 2020;152:442-3. [PMID: 33707384 DOI: 10.4103/ijmr.IJMR_2709_19] [Reference Citation Analysis]
231 Zhang F, Bai Z, Shi Y, Wang J, Li Y, Yang X. Interventional MRI-guided local delivery of agents into swine bile duct walls using MR-compatible needle-integrated balloon catheter system. NMR Biomed 2015;28:679-84. [PMID: 25900480 DOI: 10.1002/nbm.3308] [Reference Citation Analysis]
232 Buettner S, Wilson A, Margonis GA, Gani F, Ethun CG, Poultsides GA, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RC, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Maithel SK, Pawlik TM. Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study. J Gastrointest Surg 2016;20:1444-52. [PMID: 27121233 DOI: 10.1007/s11605-016-3155-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
233 Salimon M, Prieux-Klotz C, Tougeron D, Hautefeuille V, Caulet M, Gournay J, Matysiak-Budnik T, Bennouna J, Tiako Meyo M, Lecomte T, Zaanan A, Touchefeu Y. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer. 2018;118:325-330. [PMID: 29169182 DOI: 10.1038/bjc.2017.413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
234 Wang Z, Zhang Y, Chen Y, Liu S, Li C, Li X. Identification of a Ferroptosis-related Gene Signature for Predicting the Prognosis of Cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35026122 DOI: 10.1080/17474124.2022.2029700] [Reference Citation Analysis]
235 Markussen A, Jensen LH, Diness LV, Larsen FO. Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial. Cancers (Basel) 2020;12:E1975. [PMID: 32698410 DOI: 10.3390/cancers12071975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
236 Pan TT, Wang W, Jia WD, Xu GL. A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. Oncol Lett 2017;13:2957-64. [PMID: 28529557 DOI: 10.3892/ol.2017.5847] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
237 Abali H, Sezer A, Oğuzkurt L, Gürel K, Özkan U, Beşen AA, Sümbül AT, Köse F, Dişel U, Muallaoğlu S, Özyılkan Ö. Which patients with advanced cancer and biliary obstruction benefit from biliary stenting most? An analysis of prognostic factors. Support Care Cancer 2013;21:1131-5. [PMID: 23132146 DOI: 10.1007/s00520-012-1636-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
238 Chong DQ, Zhu AX. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget. 2016;7:46750-46767. [PMID: 27102149 DOI: 10.18632/oncotarget.8775] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 12.3] [Reference Citation Analysis]
239 Bridgewater J, Lopes A, Palmer D, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Valle J, Wasan H. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer 2016;114:965-71. [PMID: 27115567 DOI: 10.1038/bjc.2016.64] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
240 Tsunematsu M, Haruki K, Sakamoto T, Uwagawa T, Shiba H, Yanaga K. Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine, cisplatin, and S-1: report of a case. Surg Case Rep 2019;5:103. [PMID: 31236705 DOI: 10.1186/s40792-019-0656-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
241 Pickersgill NA, Wright AJ, Figenshau RS. Ureteropelvic junction obstruction caused by metastatic cholangiocarcinoma. Int Braz J Urol 2019;45:1266-9. [PMID: 31808416 DOI: 10.1590/S1677-5538.IBJU.2019.0053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
242 Kawasaki H, Akazawa Y, Razumilava N. Progress toward improving outcomes in patients with cholangiocarcinoma. Curr Treat Options Gastroenterol 2021;19:153-68. [PMID: 33883870 DOI: 10.1007/s11938-021-00333-2] [Reference Citation Analysis]
243 Lomphithak T, Choksi S, Mutirangura A, Tohtong R, Tencomnao T, Usubuchi H, Unno M, Sasano H, Jitkaew S. Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma. Cell Commun Signal 2020;18:161. [PMID: 33036630 DOI: 10.1186/s12964-020-00661-3] [Reference Citation Analysis]
244 Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, Sgambato A, Esposito F, Landriscina M. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives. Molecules 2020;25:E3754. [PMID: 32824685 DOI: 10.3390/molecules25163754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
245 Ma FC, Yu Q, Zeng ZM, He RQ, Mo CH, Zhong JC, Ma J, Feng ZB, Chen G, Hu XH. Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report. Onco Targets Ther 2017;10:5237-42. [PMID: 29138576 DOI: 10.2147/OTT.S146051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
246 Martin SP, Wang XW. The evolving landscape of precision medicine in primary liver cancer. Hepat Oncol 2019;6:HEP12. [PMID: 31205678 DOI: 10.2217/hep-2019-0004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
247 Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168-2179. [PMID: 24581682 DOI: 10.1016/s0140-6736(13)61903-0] [Cited by in Crossref: 783] [Cited by in F6Publishing: 471] [Article Influence: 97.9] [Reference Citation Analysis]
248 Khan TH, Veer M, Bilal M, Curran-Melendez S, Jani PM, Long GS. Leptomeningeal Carcinomatosis Associated with Gall Bladder Carcinoma: a Case Report and Review of Literature. J Gastrointest Cancer 2019;50:315-9. [PMID: 28913746 DOI: 10.1007/s12029-017-0004-0] [Reference Citation Analysis]
249 Beaulieu C, Lui A, Yusuf D, Abdelaziz Z, Randolph B, Batuyong E, Ghosh S, Bathe OF, Tam V, Spratlin JL. A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada. Curr Oncol 2021;28:417-27. [PMID: 33450805 DOI: 10.3390/curroncol28010044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
250 Wang JD, Shi WB, Shen J, Zhuang PY, Quan ZW, Wang XF, Zhou XP, Li SG, Liu YB, Yang Y. Evaluation of two modified ECF regimens in the treatment of advanced gallbladder cancer. Med Oncol 2011;28 Suppl 1:S295-300. [PMID: 21136212 DOI: 10.1007/s12032-010-9758-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
251 Kim ST, Jang KT, Lee SJ, Jang HL, Lee J, Park SH, Park YS, Lim HY, Kang WK, Park JO. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer 2015;15:530. [PMID: 26189560 DOI: 10.1186/s12885-015-1552-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
252 Patel T. Clinical diagnosis and management of intrahepatic cholangiocarcinoma. Clin Liver Dis (Hoboken) 2014;3:56-9. [PMID: 30992886 DOI: 10.1002/cld.324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
253 Mertens JC, Rizvi S, Gores GJ. Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 2018;1864:1454-60. [PMID: 28844952 DOI: 10.1016/j.bbadis.2017.08.027] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
254 Rizvi S, Gores GJ. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion 2014;89:216-24. [PMID: 24860985 DOI: 10.1159/000360791] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
255 Shirono T, Niizeki T, Iwamoto H, Shimose S, Suzuki H, Kawaguchi T, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatu R, Koga H, Torimura T. Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. J Clin Med 2021;10:987. [PMID: 33801202 DOI: 10.3390/jcm10050987] [Reference Citation Analysis]
256 Coelen RJ, Ruys AT, Besselink MG, Busch OR, van Gulik TM. Diagnostic accuracy of staging laparoscopy for detecting metastasized or locally advanced perihilar cholangiocarcinoma: a systematic review and meta-analysis. Surg Endosc 2016;30:4163-73. [PMID: 26895909 DOI: 10.1007/s00464-016-4788-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
257 Ahn DH, Bekaii-Saab T. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol 2017;8:293-301. [PMID: 28480068 DOI: 10.21037/jgo.2016.10.01] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
258 Thornblade LW, Wong P, Li D, Warner SG, Chang S, Raoof M, Kessler J, Amini A, Lin J, Chung V, Singh G, Fong Y, Melstrom LG. Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma. Cancers (Basel) 2021;13:4062. [PMID: 34439216 DOI: 10.3390/cancers13164062] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Thanee M, Padthaisong S, Suksawat M, Dokduang H, Phetcharaburanin J, Klanrit P, Titapun A, Namwat N, Wangwiwatsin A, Sa-Ngiamwibool P, Khuntikeo N, Saya H, Loilome W. Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models. Cancer Metab 2021;9:11. [PMID: 33726850 DOI: 10.1186/s40170-021-00249-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 160] [Cited by in F6Publishing: 167] [Article Influence: 80.0] [Reference Citation Analysis]
261 Sebastian NT, Tan Y, Miller ED, Williams TM, Noonan AM, Hays JL, Abdel-Misih S, Diaz DA. Association of Liver-Directed Local Therapy With Overall Survival in Adults With Metastatic Intrahepatic Cholangiocarcinoma. JAMA Netw Open. 2019;2:e1911154. [PMID: 31517963 DOI: 10.1001/jamanetworkopen.2019.11154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
262 Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3:18-34. [PMID: 24696835 DOI: 10.3978/j.issn.2304-3881.2014.02.05] [Cited by in F6Publishing: 46] [Reference Citation Analysis]
263 Venturini M, Sallemi C, Agostini G, Marra P, Cereda S, Reni M, Aldrighetti L, De Cobelli F, Del Maschio A. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study. Br J Radiol 2016;89:20160247. [PMID: 27558984 DOI: 10.1259/bjr.20160247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
264 Choi JH, Lee SH, You MS, Shin BS, Choi YH, Kang J, Jang S, Paik WH, Ryu JK, Kim YT. Step-wise endoscopic approach to palliative bilateral biliary drainage for unresectable advanced malignant hilar obstruction. Sci Rep 2019;9:13207. [PMID: 31519930 DOI: 10.1038/s41598-019-48384-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
265 Tsukiyama I, Ejiri M, Yamamoto Y, Nakao H, Yoneda M, Matsuura K, Arakawa I, Saito H, Inoue T. A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan. J Gastrointest Cancer 2017;48:326-32. [PMID: 27785685 DOI: 10.1007/s12029-016-9885-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
266 Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee JJ, Bahary N, Chu E, Streeter N, Drummond S. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer 2019;125:902-9. [PMID: 30561756 DOI: 10.1002/cncr.31872] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
267 Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 2021;7:1669-77. [PMID: 34554208 DOI: 10.1001/jamaoncol.2021.3836] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Luo X, Jia W, Huang Z, Li X, Xing B, Jiang X, Li J, Si A, Yang T, Gao C, Lau WY, Shen F. Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study. Oncotarget 2017;8:17246-57. [PMID: 27783997 DOI: 10.18632/oncotarget.12825] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
269 Kis B, El-Haddad G, Sheth RA, Parikh NS, Ganguli S, Shyn PB, Choi J, Brown KT. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729244. [PMID: 28975829 DOI: 10.1177/1073274817729244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
270 Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabró R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J, Cabellos L, Maeda M, Villacorta-Martin C, Tabrizian P, Rodriguez-Carunchio L, Castellano G, Sempoux C, Minguez B, Pawlik TM, Labgaa I, Roberts LR, Sole M, Fiel MI, Thung S, Fuster J, Roayaie S, Villanueva A, Schwartz M, Llovet JM. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol 2020;73:315-27. [PMID: 32173382 DOI: 10.1016/j.jhep.2020.03.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
271 Demeure MJ, Craig DW, Sinari S, Moses TM, Christoforides A, Dinh J, Izatt T, Aldrich J, Decker A, Baker A. Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. Genome Med. 2012;4:56. [PMID: 22762308 DOI: 10.1186/gm357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
272 Kuriyama N, Isaji S, Tanemura A, Iizawa Y, Kato H, Murata Y, Azumi Y, Kishiwada M, Mizuno S, Usui M, Sakurai H. Transhepatic Hilar Approach for Perihilar Cholangiocarcinoma: Significance of Early Judgment of Resectability and Safe Vascular Reconstruction. J Gastrointest Surg 2017;21:590-9. [PMID: 27896655 DOI: 10.1007/s11605-016-3332-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
273 Yamada M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Pulmonary Metastasis After Resection of Cholangiocarcinoma: Incidence, Resectability, and Survival. World J Surg 2017;41:1550-7. [PMID: 28105527 DOI: 10.1007/s00268-017-3877-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
274 Skipworth JR, Keane MG, Pereira SP. Update on the management of cholangiocarcinoma. Dig Dis 2014;32:570-8. [PMID: 25034290 DOI: 10.1159/000360507] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
275 Taghizadeh H, Unseld M, Schmiderer A, Djanani A, Wilthoner K, Buchinger D, Prager GW. First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. Cancer Chemother Pharmacol 2020;86:109-15. [PMID: 32556829 DOI: 10.1007/s00280-020-04094-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
276 Suyama K, Ikeda M, Suzuki E, Kojima M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Okusaka T, Furuse J. Early relapse of unresectable gallbladder cancer after discontinuation of gemcitabine monotherapy administered for 5 years in a patient who had complete response to the treatment. Case Rep Oncol 2013;6:531-7. [PMID: 24348389 DOI: 10.1159/000356080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
277 Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, Cillo U, Indraccolo S, Fabris L. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol 2018;3:40. [PMID: 30148225 DOI: 10.21037/tgh.2018.07.02] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
278 Lee H, Ross JS. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therap Adv Gastroenterol. 2017;10:507-520. [PMID: 28567120 DOI: 10.1177/1756283x17698090] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
279 Yoh T, Hatano E, Yamanaka K, Nishio T, Seo S, Taura K, Yasuchika K, Okajima H, Kaido T, Uemoto S. Is Surgical Resection Justified for Advanced Intrahepatic Cholangiocarcinoma? Liver Cancer 2016;5:280-9. [PMID: 27781200 DOI: 10.1159/000449339] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
280 Yu Y, Zhang M, Liu J, Xu B, Yang J, Wang N, Yan S, Wang F, He X, Ji G, Li Q, Miao L. Long Non-coding RNA PVT1 Promotes Cell Proliferation and Migration by Silencing ANGPTL4 Expression in Cholangiocarcinoma. Mol Ther Nucleic Acids 2018;13:503-13. [PMID: 30388624 DOI: 10.1016/j.omtn.2018.10.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
281 Huang Y, Li X, Zhao Y. Progression of targeted therapy in advanced cholangiocarcinoma. Chin J Cancer Res. 2015;27:122-127. [PMID: 25937773 DOI: 10.3978/j.issn.1000-9604.2015.04.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
282 Valery M, Facchinetti F, Malka D, Ducreux M, Friboulet L, Hollebecque A. Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors. Dig Liver Dis 2021;53:1664-5. [PMID: 34556462 DOI: 10.1016/j.dld.2021.09.001] [Reference Citation Analysis]
283 Addeo P, Jedidi I, Locicero A, Faitot F, Oncioiu C, Onea A, Bachellier P. Prognostic Impact of Tumor Multinodularity in Intrahepatic Cholangiocarcinoma. J Gastrointest Surg 2019;23:1801-9. [PMID: 30478531 DOI: 10.1007/s11605-018-4052-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
284 Riechelmann RP, Peixoto RD, Fernandes GDS, Weschenfelder RF, Prolla G, Filho DR, Andrade AC, Crosara M, Rego JFM, Gansl RC, Coimbra F, Aguiar S Jr, Carvalho E, Hoff PM, Coutinho AK. Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. Ecancermedicalscience 2020;14:1048. [PMID: 32565901 DOI: 10.3332/ecancer.2020.1048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
285 Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Fujishima F, Unno M. FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1. Cancer Sci 2018;109:3883-95. [PMID: 30302867 DOI: 10.1111/cas.13829] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
286 Bekki Y, Von Ahrens D, Takahashi H, Schwartz M, Gunasekaran G. Recurrent Intrahepatic Cholangiocarcinoma - Review. Front Oncol 2021;11:776863. [PMID: 34746017 DOI: 10.3389/fonc.2021.776863] [Reference Citation Analysis]
287 Kiriyama M, Kaneoka Y, Maeda A, Takayama Y, Takahashi T, Seita K. Laparoscopic liver resection after laparoscopic pancreatoduodenectomy for liver metastases of ampulla of Vater adenocarcinoma. Surg Case Rep 2020;6:268. [PMID: 33030624 DOI: 10.1186/s40792-020-01043-0] [Reference Citation Analysis]
288 Wiggers JK, Groot Koerkamp B, van Klaveren D, Coelen RJ, Nio CY, Allen PJ, Besselink MG, Busch OR, D'Angelica MI, DeMatteo RP, Kingham TP, van Gulik TM, Jarnagin WR. Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging. J Am Coll Surg. 2018;227:238-246.e2. [PMID: 29627334 DOI: 10.1016/j.jamcollsurg.2018.03.041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
289 Akabane S, Ohira M, Kobayashi T, Kuroda S, Tanimine N, Shimizu S, Tahara H, Ide K, Ishiyama K, Egi H, Tanabe K, Sentani K, Yasui W, Ohdan H. Intrahepatic cholangiocarcinoma coinciding with a liver metastasis from a rectal carcinoma: a case report. Surg Case Rep 2016;2:94. [PMID: 27612869 DOI: 10.1186/s40792-016-0222-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
290 Vignone A, Biancaniello F, Casadio M, Pesci L, Cardinale V, Ridola L, Alvaro D. Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review. J Clin Med 2021;10:4901. [PMID: 34768421 DOI: 10.3390/jcm10214901] [Reference Citation Analysis]
291 Hirata K, Kuwatani M, Suda G, Ishikawa M, Sugiura R, Kato S, Kawakubo K, Sakamoto N. A Novel Approach for the Genetic Analysis of Biliary Tract Cancer Specimens Obtained Through Endoscopic Ultrasound-Guided Fine Needle Aspiration Using Targeted Amplicon Sequencing. Clin Transl Gastroenterol 2019;10:e00022. [PMID: 30908307 DOI: 10.14309/ctg.0000000000000022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
292 Mao ZY, Guo XC, Su D, Wang LJ, Zhang TT, Bai L. Prognostic Factors of Cholangiocarcinoma After Surgical Resection: A Retrospective Study of 293 Patients. Med Sci Monit 2015;21:2375-81. [PMID: 26269932 DOI: 10.12659/MSM.893586] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
293 Marchan EM, Landry JC. Neoadjuvant chemoradiation followed by orthotopic liver transplantation in cholangiocarcinomas: the emory experience. J Gastrointest Oncol. 2016;7:248-254. [PMID: 27034793 DOI: 10.3978/j.issn.2078-6891.2015.117] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
294 Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R, Clarke P, Bosma E, Simbolo M, Scarpa A, Yu S, Cole R, Smyth E, Mateos JF, Begum R, Hezelova B, Eltahir Z, Wotherspoon A, Fotiadis N, Bali MA, Nepal C, Khan K, Stubbs M, Hahne JC, Gasparini P, Guzzardo V, Croce CM, Eccles S, Fassan M, Cunningham D, Andersen JB, Workman P, Valeri N, Braconi C. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology. 2018;154:1066-1079.e5. [PMID: 29113809 DOI: 10.1053/j.gastro.2017.10.043] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 9.6] [Reference Citation Analysis]
295 Pearngam P, Kumkate S, Okada S, Janvilisri T. Andrographolide Inhibits Cholangiocarcinoma Cell Migration by Down-Regulation of Claudin-1 via the p-38 Signaling Pathway. Front Pharmacol 2019;10:827. [PMID: 31404237 DOI: 10.3389/fphar.2019.00827] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
296 Kwak TW, Kim DH, Jeong YI, Kang DH. Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells. J Nanobiotechnology. 2015;13:60. [PMID: 26410576 DOI: 10.1186/s12951-015-0122-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
297 Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol 2020;6:888-94. [PMID: 32352498 DOI: 10.1001/jamaoncol.2020.0930] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 59.0] [Reference Citation Analysis]
298 Doherty MK, McNamara MG, Aneja P, McInerney E, Moignard S, Horgan AM, Jiang H, Panzarella T, Jang R, Dhani N, Hedley D, Knox JJ. Long term responders to palliative chemotherapy for advanced biliary tract cancer. J Gastrointest Oncol 2017;8:352-60. [PMID: 28480074 DOI: 10.21037/jgo.2017.03.06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
299 Rizzo A. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. Cancer Treat Res Commun 2021;27:100360. [PMID: 33799005 DOI: 10.1016/j.ctarc.2021.100360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
300 Wylie NS, Sokumbi O, Starr JS. Painful Eruptions in a Patient With Cholangiocarcinoma Treated With Fibroblast Growth Factor Receptor Inhibitor. JAMA Oncol 2021;7:1891-2. [PMID: 34709371 DOI: 10.1001/jamaoncol.2021.5578] [Reference Citation Analysis]
301 Yoshida A, Takenaka M, Takashima K, Tanaka H, Okamoto A, Yamazaki T, Nakai A, Omoto S, Minaga K, Kamata K, Yamao K, Komeda Y, Nishida N, Kudo M. Usefulness of the Novel Snare-over-the-Guidewire Method for Transpapillary Plastic Stent Replacement (with Video). J Clin Med 2021;10:2858. [PMID: 34203200 DOI: 10.3390/jcm10132858] [Reference Citation Analysis]
302 Wu HJ, Chu PY. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. Int J Mol Sci 2019;20:E4154. [PMID: 31450710 DOI: 10.3390/ijms20174154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
303 Jethwa KR, Sannapaneni S, Mullikin TC, Harmsen WS, Petersen MM, Antharam P, Laughlin B, Mahipal A, Halfdanarson TR, Merrell KW, Neben-Wittich M, Sio TT, Haddock MG, Hallemeier CL. Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. J Gastrointest Oncol. 2020;11:1408-1420. [PMID: 33457010 DOI: 10.21037/jgo-20-245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
304 Ghosn M, Kourie HR, El Rassy E, Chebib R, El Karak F, Hanna C, Nasr D. Optimum chemotherapy for the management of advanced biliary tract cancer. World J Gastroenterol 2015; 21(14): 4121-4125 [PMID: 25892861 DOI: 10.3748/wjg.v21.i14.4121] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
305 Won HS, Lee MA, Chung ES, Kim DG, You YK, Hong TH, Lee IS. Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer. BMC Cancer 2010;10:564. [PMID: 20955617 DOI: 10.1186/1471-2407-10-564] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
306 Wakai T, Nagahashi M, Shimada Y, Prasoon P, Sakata J. Genetic analysis in the clinical management of biliary tract cancer. Ann Gastroenterol Surg 2020;4:316-23. [PMID: 32724874 DOI: 10.1002/ags3.12334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
307 Sahara K, Farooq SA, Tsilimigras DI, Merath K, Paredes AZ, Wu L, Mehta R, Hyer JM, Endo I, Pawlik TM. Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. Hepatobiliary Surg Nutr 2020;9:13-24. [PMID: 32140475 DOI: 10.21037/hbsn.2019.07.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
308 Nepal C, O'Rourke CJ, Oliveira DVNP, Taranta A, Shema S, Gautam P, Calderaro J, Barbour A, Raggi C, Wennerberg K, Wang XW, Lautem A, Roberts LR, Andersen JB. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology 2018;68:949-63. [PMID: 29278425 DOI: 10.1002/hep.29764] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
309 Patel SH, Kooby DA, Staley CA, Sarmiento JM, Maithel SK. The prognostic importance of lymphovascular invasion in cholangiocarcinoma above the cystic duct: a new selection criterion for adjuvant therapy? HPB (Oxford). 2011;13:605-611. [PMID: 21843260 DOI: 10.1111/j.1477-2574.2011.00335.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
310 Utsumi M, Aoki H, Kunitomo T, Mushiake Y, Kanaya N, Yasuhara I, Arata T, Katsuda K, Tanakaya K, Takeuchi H. Surgical resection of splenic metastasis from the adenosquamous gallbladder carcinoma: A case report. Int J Surg Case Rep 2016;20:109-13. [PMID: 26852359 DOI: 10.1016/j.ijscr.2016.01.032] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
311 Leal P, Garcia P, Sandoval A, Buchegger K, Weber H, Tapia O, Roa JC. AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther 2013;6:1373-84. [PMID: 24124380 DOI: 10.2147/OTT.S46897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.1] [Reference Citation Analysis]
312 Wang Y, Yu H, Xie X, Deng T, Ye L, Wu L, Ding X, Yang Z, Zhu Q, Li J, Zheng Y, Yu Z, Chen G. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway. Oncogene 2021;40:4324-37. [PMID: 34079085 DOI: 10.1038/s41388-021-01844-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Toyohara T, Nakazawa T, Zakharia K, Shimizu S, Miyabe K, Harada K, Notohara K, Yamada T, Hayashi K, Naitoh I, Hayashi K, Kataoka H. IgG4-related Sclerosing Cholangitis Complicated with Cholangiocarcinoma and Detected by Forkhead Box P3 Immunohistochemical Staining. Intern Med 2021;60:859-66. [PMID: 33087673 DOI: 10.2169/internalmedicine.5920-20] [Reference Citation Analysis]
314 Okumura K, Gogna S, Gachabayov M, Felsenreich DM, McGuirk M, Rojas A, Quintero L, Seshadri R, Gu K, Dong XD. Gallbladder cancer: Historical treatment and new management options. World J Gastrointest Oncol 2021; 13(10): 1317-1335 [PMID: 34721769 DOI: 10.4251/wjgo.v13.i10.1317] [Reference Citation Analysis]
315 Chiang NJ, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 2021;11:97. [PMID: 33451059 DOI: 10.3390/biom11010097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
316 Yachida S, Wood LD, Suzuki M, Takai E, Totoki Y, Kato M, Luchini C, Arai Y, Nakamura H, Hama N, Elzawahry A, Hosoda F, Shirota T, Morimoto N, Hori K, Funazaki J, Tanaka H, Morizane C, Okusaka T, Nara S, Shimada K, Hiraoka N, Taniguchi H, Higuchi R, Oshima M, Okano K, Hirono S, Mizuma M, Arihiro K, Yamamoto M, Unno M, Yamaue H, Weiss MJ, Wolfgang CL, Furukawa T, Nakagama H, Vogelstein B, Kiyono T, Hruban RH, Shibata T. Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. Cancer Cell. 2016;29:229-240. [PMID: 26806338 DOI: 10.1016/j.ccell.2015.12.012] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 13.2] [Reference Citation Analysis]
317 McNamara MG, Bridgewater J, Palmer DH, Faluyi O, Wasan H, Patel A, Ryder WD, Barber S, Gnanaranjan C, Ghazaly E, Evans TRJ, Valle JW. A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). Oncologist 2021;26:e669-78. [PMID: 33210382 DOI: 10.1002/onco.13598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
318 Hajibandeh S, Hajibandeh S, Satyadas T. Endoscopic Versus Percutaneous Preoperative Biliary Drainage in Patients With Klatskin Tumor Undergoing Curative Surgery: A Systematic Review and Meta-Analysis of Short-Term and Long-Term Outcomes. Surg Innov 2020;27:279-90. [PMID: 32172684 DOI: 10.1177/1553350620911291] [Reference Citation Analysis]
319 Bednarsch J, Tan X, Czigany Z, Liu D, Lang SA, Sivakumar S, Kather JN, Appinger S, Rosin M, Boroojerdi S, Dahl E, Gaisa NT, den Dulk M, Coolsen M, Ulmer TF, Neumann UP, Heij LR. The Presence of Small Nerve Fibers in the Tumor Microenvironment as Predictive Biomarker of Oncological Outcome Following Partial Hepatectomy for Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:3661. [PMID: 34359564 DOI: 10.3390/cancers13153661] [Reference Citation Analysis]
320 Spolverato G, Glavas D, Hewitt DB, Brown ZJ, Capelli G, Bergamo F, Rizzato MD, Pawlik TM. Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs. Expert Opin Pharmacother 2021;:1-9. [PMID: 34964678 DOI: 10.1080/14656566.2021.2020250] [Reference Citation Analysis]
321 Faugeras L, Cantineau G, Daisne JF, Gustin T, D'hondt L. Intramedullary spinal cord metastasis of cholangiocarcinoma: a case report. BMC Res Notes 2015;8:41. [PMID: 25889352 DOI: 10.1186/s13104-015-0998-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
322 Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:669-680. [PMID: 26172134 DOI: 10.1111/hpb.12441] [Cited by in Crossref: 177] [Cited by in F6Publishing: 209] [Article Influence: 29.5] [Reference Citation Analysis]
323 Seehofer D, Kamphues C, Neuhaus P. [Resection of Klatskin tumors]. Chirurg 2012;83:221-8. [PMID: 22406679 DOI: 10.1007/s00104-011-2177-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
324 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 18.0] [Reference Citation Analysis]
325 Kamarajah S, Giovinazzo F, Roberts KJ, Punia P, Sutcliffe RP, Marudanayagam R, Chatzizacharias N, Isaac J, Mirza DF, Muiesan P, Dasari BV. The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: Review of literature and pooled analysis. Ann Hepatobiliary Pancreat Surg. 2020;24:6-16. [PMID: 32181423 DOI: 10.14701/ahbps.2020.24.1.6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
326 Judée F, Vaquero J, Guégan S, Fouassier L, Dufour T. Atmospheric pressure plasma jets applied to cancerology: correlating electrical configuration with in vivo toxicity and therapeutic efficiency. J Phys D: Appl Phys 2019;52:245201. [DOI: 10.1088/1361-6463/ab0fbb] [Cited by in Crossref: 10] [Article Influence: 3.3] [Reference Citation Analysis]
327 Schueneman A, Goggins M, Ensor J, Saka B, Neishaboori N, Lee S, Maitra A, Varadhachary G, Rezaee N, Wolfgang C, Adsay V, Wang H, Overman MJ. Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma. Br J Cancer. 2015;113:64-68. [PMID: 25989273 DOI: 10.1038/bjc.2015.172] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
328 Kriegsmann M, Roessler S, Kriegsmann K, Renner M, Longuespée R, Albrecht T, Loeffler M, Singer S, Mehrabi A, Vogel MN, Pathil A, Köhler B, Springfeld C, Rupp C, Weiss KH, Goeppert B. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies. BMC Cancer 2019;19:72. [PMID: 30646854 DOI: 10.1186/s12885-018-5254-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
329 Gkika E, Hallauer L, Kirste S, Adebahr S, Bartl N, Neeff HP, Fritsch R, Brass V, Nestle U, Grosu AL, Brunner TB. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. BMC Cancer 2017;17:781. [PMID: 29162055 DOI: 10.1186/s12885-017-3788-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
330 Salati M, Caputo F, Baldessari C, Galassi B, Grossi F, Dominici M, Ghidini M. IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting. Cancers (Basel) 2020;12:E3310. [PMID: 33182517 DOI: 10.3390/cancers12113310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
331 Posch F, Prinz F, Balihodzic A, Mayr C, Kiesslich T, Klec C, Jonas K, Barth DA, Riedl JM, Gerger A, Pichler M. MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms. Cancers (Basel) 2021;13:3996. [PMID: 34439151 DOI: 10.3390/cancers13163996] [Reference Citation Analysis]
332 Watanabe G, Uchinami H, Yoshioka M, Nanjo H, Yamamoto Y. Prognosis analysis of sarcomatous intrahepatic cholangiocarcinoma from a review of the literature. Int J Clin Oncol. 2014;19:490-496. [PMID: 23824556 DOI: 10.1007/s10147-013-0586-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
333 Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15:819-828. [PMID: 24852116 DOI: 10.1016/s1470-2045(14)70212-8] [Cited by in Crossref: 220] [Cited by in F6Publishing: 120] [Article Influence: 27.5] [Reference Citation Analysis]
334 Fabritius MP, Ben Khaled N, Kunz WG, Ricke J, Seidensticker M. Image-Guided Local Treatment for Unresectable Intrahepatic Cholangiocarcinoma-Role of Interventional Radiology. J Clin Med 2021;10:5574. [PMID: 34884275 DOI: 10.3390/jcm10235574] [Reference Citation Analysis]
335 Wan M, Sun B, Cui YF. Bile duct carcinoma: diagnosis and treatment based on AJCC staging. Shijie Huaren Xiaohua Zazhi 2011; 19(34): 3471-3476 [DOI: 10.11569/wcjd.v19.i34.3471] [Reference Citation Analysis]
336 Suzuki Y, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, Imaoka H, Ohno I, Mitsunaga S, Ikeda M. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. J Gastroenterol 2019;54:281-90. [PMID: 30298469 DOI: 10.1007/s00535-018-1518-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
337 Inoue H, Todaka A, Yamazaki K, Fushiki K, Shirasu H, Kawakami T, Tsushima T, Hamauchi S, Yokota T, Machida N, Fukutomi A, Onozawa Y, Andoh A, Yasui H. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer. Invest New Drugs 2021;39:1399-404. [PMID: 33835357 DOI: 10.1007/s10637-021-01098-2] [Reference Citation Analysis]
338 Kim RD, Alberts SR, Peña C, Genvresse I, Ajavon-Hartmann A, Xia C, Kelly A, Grilley-Olson JE. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. Br J Cancer 2018;118:462-70. [PMID: 29348486 DOI: 10.1038/bjc.2017.428] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
339 O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer 2018;124:1374-82. [PMID: 29338080 DOI: 10.1002/cncr.31218] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
340 Chopra S, Mathew AS, Engineer R, Shrivastava SK. Positioning high-dose radiation in multidisciplinary management of unresectable cholangiocarcinomas: review of current evidence. Indian J Gastroenterol 2014;33:401-7. [PMID: 25135161 DOI: 10.1007/s12664-014-0495-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
341 Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther 2021;14:1341-66. [PMID: 33658799 DOI: 10.2147/OTT.S297643] [Reference Citation Analysis]
342 Wiggers JK, Groot Koerkamp B, Ovadia Z, Busch OR, Gouma DJ, van Gulik TM. Patterns of recurrence after resection of gallbladder cancer without routine extrahepatic bile duct resection. HPB (Oxford) 2014;16:635-40. [PMID: 24246159 DOI: 10.1111/hpb.12188] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
343 Sommer CM, Kauczor HU, Pereira PL. Locoregional Therapies of Cholangiocarcinoma. Visc Med 2016;32:414-20. [PMID: 28229076 DOI: 10.1159/000453010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
344 Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, Qian M, Wang XW, Ho M. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer 2010;1:141-9. [PMID: 20922056 DOI: 10.7150/jca.1.141] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
345 San TT, Khaenam P, Prachayasittikul V, Sripa B, Kunkeaw N, Chan-On W. Curcumin enhances chemotherapeutic effects and suppresses ANGPTL4 in anoikis-resistant cholangiocarcinoma cells.Heliyon. 2020;6:e03255. [PMID: 32051864 DOI: 10.1016/j.heliyon.2020.e03255] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
346 Karanicolas PJ, Ko YJ. Transarterial Therapy for Primary Liver Carcinomas: A Crack in the Armor? Ann Surg Oncol 2015;22:4111-2. [PMID: 26228107 DOI: 10.1245/s10434-015-4776-9] [Reference Citation Analysis]
347 Ahn DH, Bekaii-Saab T. Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book 2014;:112-5. [PMID: 24857067 DOI: 10.14694/EdBook_AM.2014.34.112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
348 Li Q, Yin X, Wang W, Zhan M, Zhao B, Hou Z, Wang J. The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine. Oncol Lett. 2016;11:474-480. [PMID: 26870236 DOI: 10.3892/ol.2015.3879] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
349 Tang Z, Yang Y, Wang X, Meng W, Li X. Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma. BMJ Open 2019;9:e021693. [PMID: 30700476 DOI: 10.1136/bmjopen-2018-021693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
350 Tajima H, Ohta T, Shinbashi H, Hirose A, Tsukada T, Okamoto K, Nakanuma S, Sakai S, Furukawa H, Makino I, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Nakagawara H, Miyashita T, Fujita H, Takamura H, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Mouri H, Ohtsubo K. Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report. Oncol Lett 2012;4:1281-4. [PMID: 23226802 DOI: 10.3892/ol.2012.909] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
351 Xiong F, Gong J, Wang Q. Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report. Onco Targets Ther 2020;13:6385-91. [PMID: 32753881 DOI: 10.2147/OTT.S250454] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
352 Tang ZH, Lv LS, Lin PY, Chen ZS, Quan ZW. Viewing cellular origin of intrahepatic cholangiocarcinoma from perspective of tumor heterogeneity. Shijie Huaren Xiaohua Zazhi 2015; 23(33): 5255-5262 [DOI: 10.11569/wcjd.v23.i33.5255] [Reference Citation Analysis]
353 Kim YH, Hong EK, Kong SY, Han SS, Kim SH, Rhee JK, Hwang SK, Park SJ, Kim TM. Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. Oncotarget 2016;7:23825-36. [PMID: 27009864 DOI: 10.18632/oncotarget.8183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
354 Bankov K, Döring C, Schneider M, Hartmann S, Winkelmann R, Albert JG, Bechstein WO, Zeuzem S, Hansmann ML, Peveling-Oberhag J, Walter D. Sequencing of intraductal biopsies is feasible and potentially impacts clinical management of patients with indeterminate biliary stricture and cholangiocarcinoma. Clin Transl Gastroenterol 2018;9:151. [PMID: 29712892 DOI: 10.1038/s41424-018-0015-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
355 Bupathi M, Ahn DH, Bekaii-Saab T. Therapeutic options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6:91-100. [PMID: 28503556 DOI: 10.21037/hbsn.2016.12.12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
356 Okumura T, Nakamura J, Kai K, Ide Y, Nakamura H, Koga H, Ide T, Miyoshi A, Kitahara K, Noshiro H. Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case. World J Surg Oncol 2014;12:326. [PMID: 25367161 DOI: 10.1186/1477-7819-12-326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
357 Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst 2021;113:27-37. [PMID: 32339229 DOI: 10.1093/jnci/djaa061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
358 Deng YL, Li J. Adjuvant Chemotherapy in Resectable Gallbladder Cancer is Underutilized Despite Benefits in Node-Positive Patients. Ann Surg Oncol 2020;27:940-1. [PMID: 32989657 DOI: 10.1245/s10434-020-09167-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
359 Albrecht T, Rausch M, Rössler S, Albrecht M, Braun JD, Geissler V, Mehrabi A, Vogel MN, Pathil-Warth A, Mechtersheimer G, Renner M, Rupp C, Weiss KH, Busch E, Köhler B, Springfeld C, Schirmacher P, Goeppert B. HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis. BMC Cancer 2019;19:1191. [PMID: 31805897 DOI: 10.1186/s12885-019-6320-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
360 Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals (Basel) 2021;14:51. [PMID: 33440754 DOI: 10.3390/ph14010051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
361 Lu BJ, Cao XD, Yuan N, Liu NN, Azami NL, Sun MY. Concomitant adenosquamous carcinoma and cystadenocarcinoma of the extrahepatic bile duct: A case report. World J Clin Cases 2019; 7(2): 215-220 [PMID: 30705898 DOI: 10.12998/wjcc.v7.i2.215] [Reference Citation Analysis]
362 Rizzo A, Tavolari S, Ricci AD, Frega G, Palloni A, Relli V, Salati M, Fenocchio E, Massa A, Aglietta M, Brandi G. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. Cancers (Basel) 2020;12:E3256. [PMID: 33158162 DOI: 10.3390/cancers12113256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
363 Goenka MK, Goenka U. Palliation: Hilar cholangiocarcinoma. World J Hepatol 2014; 6(8): 559-569 [PMID: 25232449 DOI: 10.4254/wjh.v6.i8.559] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
364 Abou-Alfa GK, Geschwind JF, Choti M, d'Angelica MI. Consensus conference on intrahepatic cholangiocarcinoma. HPB (Oxford) 2015;17:661-3. [PMID: 26172131 DOI: 10.1111/hpb.12438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
365 Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:691-699. [PMID: 26172136 DOI: 10.1111/hpb.12450] [Cited by in Crossref: 169] [Cited by in F6Publishing: 190] [Article Influence: 28.2] [Reference Citation Analysis]
366 Ioffe D, Phull P, Dotan E. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Manag Res 2021;13:8085-98. [PMID: 34737637 DOI: 10.2147/CMAR.S276104] [Reference Citation Analysis]
367 Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. BMC Cancer 2019;19:55. [PMID: 30634942 DOI: 10.1186/s12885-018-5223-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
368 Levillain H, Duran Derijckere I, Ameye L, Guiot T, Braat A, Meyer C, Vanderlinden B, Reynaert N, Hendlisz A, Lam M, Deroose CM, Ahmadzadehfar H, Flamen P. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging 2019;46:2270-9. [PMID: 31324943 DOI: 10.1007/s00259-019-04427-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
369 Uji M, Mizuno T, Ebata T, Sugawara G, Igami T, Uehara K, Nagino M. A case of advanced intrahepatic cholangiocarcinoma accidentally, but successfully, treated with capecitabine plus oxaliplatin (CAPOX) therapy combined with bevacizumab: a case report. Surg Case Rep 2016;2:63. [PMID: 27342988 DOI: 10.1186/s40792-016-0191-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
370 Yu J, Zhang W, Lu B, Qian H, Tang H, Zhu Z, Yuan X, Ren P. miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M. Oncol Lett 2018;15:3305-12. [PMID: 29435072 DOI: 10.3892/ol.2017.7708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
371 Parzen JS, Hartsell W, Chang J, Apisarnthanarax S, Molitoris J, Durci M, Tsai H, Urbanic J, Ashman J, Vargas C, Stevens C, Kabolizadeh P. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group. Radiat Oncol 2020;15:255. [PMID: 33148296 DOI: 10.1186/s13014-020-01703-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
372 Seto K, Shoda J, Horibe T, Warabi E, Kohno M, Yanagawa T, Bukawa H, Nakanuma Y, Kawakami K. Targeting interleukin-4 receptor alpha by hybrid Peptide for novel biliary tract cancer therapy. Int J Hepatol 2014;2014:584650. [PMID: 24868471 DOI: 10.1155/2014/584650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
373 Kim H, Hwang H, Lee H, Hong HJ. L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation. Mol Cells 2017;40:363-70. [PMID: 28535665 DOI: 10.14348/molcells.2017.2282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
374 Posch F, Hofer S, Thaler J, Hell L, Königsbrügge O, Grilz E, Mauracher LM, Gebhart J, Marosi C, Jilma B, Pabinger I, Ay C. Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. Transl Res 2020;215:41-56. [PMID: 31525325 DOI: 10.1016/j.trsl.2019.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
375 Azad T, Rezaei R, Surendran A, Singaravelu R, Boulton S, Dave J, Bell JC, Ilkow CS. Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis. Cancers (Basel) 2020;12:E2042. [PMID: 32722184 DOI: 10.3390/cancers12082042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
376 Garcia-Pardo M, Ortega L, Fernández-Aceñero MJ, García Alfonso P, Martín M, Muñoz AJ. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study. J Gastrointest Cancer 2021;52:814-8. [PMID: 33683644 DOI: 10.1007/s12029-021-00622-0] [Reference Citation Analysis]
377 Feng M, Pan Y, Kong R, Shu S. Therapy of Primary Liver Cancer. Innovation (N Y) 2020;1:100032. [PMID: 32914142 DOI: 10.1016/j.xinn.2020.100032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
378 Sinn M, Nicolaou A, Ricke J, Podrabsky P, Seehofer D, Gebauer B, Pech M, Neuhaus P, Dörken B, Riess H, Hildebrandt B. Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161). BMC Gastroenterol 2013;13:125. [PMID: 23927554 DOI: 10.1186/1471-230X-13-125] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
379 de Savornin Lohman E, de Bitter T, Verhoeven R, van der Geest L, Hagendoorn J, Haj Mohammad N, Daams F, Klümpen HJ, van Gulik T, Erdmann J, de Boer M, Hoogwater F, Koerkamp BG, Braat A, Verheij J, Nagtegaal I, van Laarhoven C, van den Boezem P, van der Post R, de Reuver P. Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort. Cancers (Basel) 2020;12:E918. [PMID: 32283627 DOI: 10.3390/cancers12040918] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
380 Chai Y. Immunotherapy of biliary tract cancer. Tumour Biol 2016;37:2817-21. [PMID: 26729196 DOI: 10.1007/s13277-015-4743-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
381 Chen HD, Huang CS, Xu QC, Li F, Huang XT, Wang JQ, Li SJ, Zhao W, Yin XY. Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma. Int J Biol Sci 2020;16:1207-17. [PMID: 32174795 DOI: 10.7150/ijbs.39779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
382 Lee TY, Cheon YK, Shim CS. Current status of photodynamic therapy for bile duct cancer. Clin Endosc. 2013;46:38-44. [PMID: 23423177 DOI: 10.5946/ce.2013.46.1.38] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
383 Plentz RR, Malek NP. Systemic Therapy of Cholangiocarcinoma. Visc Med 2016;32:427-30. [PMID: 28229078 DOI: 10.1159/000453084] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
384 Yang L, Shan J, Shan L, Saxena A, Bester L, Morris DL. Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Oncol 2015;6:570-88. [PMID: 26487951 DOI: 10.3978/j.issn.2078-6891.2015.055] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
385 Czauderna C, Kirstein MM, Tews HC, Vogel A, Marquardt JU. Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2803. [PMID: 34202401 DOI: 10.3390/jcm10132803] [Reference Citation Analysis]
386 McMillan RR, Javle M, Kodali S, Saharia A, Mobley C, Heyne K, Hobeika MJ, Lunsford KE, Victor DW 3rd, Shetty A, McFadden RS, Abdelrahim M, Kaseb A, Divatia M, Yu N, Nolte Fong J, Moore LW, Nguyen DT, Graviss EA, Gaber AO, Vauthey JN, Ghobrial RM. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant 2021. [PMID: 34856069 DOI: 10.1111/ajt.16906] [Reference Citation Analysis]
387 Sharon E, Zhang J, Hollevoet K, Steinberg SM, Pastan I, Onda M, Gaedcke J, Ghadimi BM, Ried T, Hassan R. Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. Clin Chem Lab Med. 2012;50:721-725. [PMID: 22149739 DOI: 10.1515/cclm.2011.816] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
388 Lamarca A, Galdy S, Barriuso J, Moghadam S, Beckett E, Rogan J, Backen A, Billington C, McNamara MG, Hubner RA, Cramer A, Valle JW. The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PLoS One 2018;13:e0206007. [PMID: 30335866 DOI: 10.1371/journal.pone.0206007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
389 Kim R, Chiorean EG, Amin M, Rocha-Lima CMS, Gandhi J, Harris WP, Song T, Portnoy D. Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment. Br J Cancer 2017;117:189-94. [PMID: 28632730 DOI: 10.1038/bjc.2017.160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
390 Hu Y, Lin H, Hao M, Zhou Y, Chen Q, Chen Z. Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study. Cancer Manag Res 2020;12:5345-51. [PMID: 32753952 DOI: 10.2147/CMAR.S254955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Coelen RJS, Vogel JA, Vroomen LGPH, Roos E, Busch ORC, van Delden OM, Delft FV, Heger M, van Hooft JE, Kazemier G, Klümpen HJ, van Lienden KP, Rauws EAJ, Scheffer HJ, Verheul HM, Vries J, Wilmink JW, Zonderhuis BM, Besselink MG, van Gulik TM, Meijerink MR. Ablation with irreversible electroporation in patients with advanced perihilar cholangiocarcinoma (ALPACA): a multicentre phase I/II feasibility study protocol. BMJ Open 2017;7:e015810. [PMID: 28864693 DOI: 10.1136/bmjopen-2016-015810] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
392 Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99-109. [PMID: 24634588 DOI: 10.2147/clep.s37357.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
393 Wu CE, Chen MH, Yeh CN. mTOR Inhibitors in Advanced Biliary Tract Cancers. Int J Mol Sci 2019;20:E500. [PMID: 30682771 DOI: 10.3390/ijms20030500] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
394 Kim YS, Jeong CY, Song HN, Kim TH, Kim HJ, Lee YJ, Hong SC. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection. Chin J Cancer 2017;36:9. [PMID: 28086990 DOI: 10.1186/s40880-017-0182-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
395 Moriwaki T, Yamamoto Y, Gosho M, Kobayashi M, Sugaya A, Yamada T, Endo S, Hyodo I. Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy. Br J Cancer 2016;114:881-8. [PMID: 27031848 DOI: 10.1038/bjc.2016.83] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
396 Loaiza-Bonilla A, Furth EE, Morrissette JJ. Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies. Hepat Oncol 2015;2:359-70. [PMID: 30191018 DOI: 10.2217/hep.15.20] [Reference Citation Analysis]
397 Vaquero J, Lobe C, Fouassier L. Unveiling resistance mechanisms to EGFR inhibitors in cholangiocarcinoma. Oncotarget 2018;9:37274-5. [PMID: 30647862 DOI: 10.18632/oncotarget.26403] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
398 Leoni S, Sansone V, Lorenzo S, Ielasi L, Tovoli F, Renzulli M, Golfieri R, Spinelli D, Piscaglia F. Treatment of Combined Hepatocellular and Cholangiocarcinoma. Cancers (Basel) 2020;12:E794. [PMID: 32224916 DOI: 10.3390/cancers12040794] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
399 Tada M, Nakai Y, Sasaki T, Hamada T, Nagano R, Mohri D, Miyabayashi K, Yamamoto K, Kogure H, Kawakubo K, Ito Y, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Isayama H, Omata M, Koike K. Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World J Clin Oncol 2011; 2(3): 158-163 [PMID: 21611090 DOI: 10.5306/wjco.v2.i3.158] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
400 Vaquero J, Judée F, Vallette M, Decauchy H, Arbelaiz A, Aoudjehane L, Scatton O, Gonzalez-Sanchez E, Merabtene F, Augustin J, Housset C, Dufour T, Fouassier L. Cold-Atmospheric Plasma Induces Tumor Cell Death in Preclinical In Vivo and In Vitro Models of Human Cholangiocarcinoma. Cancers (Basel) 2020;12:E1280. [PMID: 32438553 DOI: 10.3390/cancers12051280] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
401 Wang QL, Li XJ, Zhao K, Liu BO, Ye XM. Synchronous double primary cancer - intrahepatic cholangiocarcinoma with bone metastases and thyroid carcinoma: A case report. Oncol Lett 2015;10:3799-802. [PMID: 26788211 DOI: 10.3892/ol.2015.3822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
402 Ding Y, Han X, Sun Z, Tang J, Wu Y, Wang W. Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy. Front Oncol 2021;11:691380. [PMID: 34527576 DOI: 10.3389/fonc.2021.691380] [Reference Citation Analysis]
403 Castelo Branco M, Estevinho F, Correia Pinto J, Honavar M, Raposo C, Silva AC, Sottomayor C. Gallbladder Cancer: Complete Resection after Second Line Treatment in Stage IV Disease. J Gastrointest Cancer 2019;50:564-7. [PMID: 29292472 DOI: 10.1007/s12029-017-0044-5] [Reference Citation Analysis]
404 Wei K, Li M, Zöller M, Wang M, Mehrabi A, Hoffmann K. Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma. Cell Death Dis 2019;10:231. [PMID: 30850583 DOI: 10.1038/s41419-019-1460-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
405 Xie X, Wang Y, Zhang S, Li J, Yu Z, Ding X, Ye L, Gong P, Zhu Q, Li J, Chen Z, Yao X, Du Z, Zeng Q, Chen H, Yang Z, Chen G. A novel five-lncRNA signature panel improves high-risk survival prediction in patients with cholangiocarcinoma. Aging (Albany NY) 2021;13:2959-81. [PMID: 33472169 DOI: 10.18632/aging.202446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
406 Sato Y, Hara T, Takami Y, Wada Y, Ryu T, Sasaki S, Yoshitomi M, Momosaki S, Murakami M, Hijioka M, Kaku T, Kawabe K, Saitsu H. Conversion surgery for initially unresectable carcinoma of the ampulla of Vater following pathological complete response to chemotherapy: a case report. Surg Case Rep 2019;5:122. [PMID: 31363940 DOI: 10.1186/s40792-019-0680-z] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
407 Kodali S, Shetty A, Shekhar S, Victor DW, Ghobrial RM. Management of Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2368. [PMID: 34072277 DOI: 10.3390/jcm10112368] [Reference Citation Analysis]
408 Li W, Ma Z, Fu X, Hao Z, Shang H, Shi J, Lei M, Xu M, Ning S, Hua X. Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report. Ann Transl Med 2021;9:1487. [PMID: 34734039 DOI: 10.21037/atm-21-3681] [Reference Citation Analysis]
409 Haug AR, Heinemann V, Bruns CJ, Hoffmann R, Jakobs T, Bartenstein P, Hacker M. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2011;38:1037-1045. [PMID: 21308371 DOI: 10.1007/s00259-011-1736-x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.9] [Reference Citation Analysis]
410 Currie BM, Soulen MC. Decision Making: Intra-arterial Therapies for Cholangiocarcinoma-TACE and TARE. Semin Intervent Radiol 2017;34:92-100. [PMID: 28579676 DOI: 10.1055/s-0037-1602591] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
411 Huang WK, Yeh CN. The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma. Biomolecules. 2020;10. [PMID: 33007962 DOI: 10.3390/biom10101396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
412 Buettner S, van Vugt JLA, Gaspersz MP, Coelen RJS, Roos E, Labeur TA, Margonis GA, Ethun CG, Maithel SK, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, IJzermans JNM, van Gulik TM, Pawlik TM, Groot Koerkamp B. Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases. HPB (Oxford) 2017;19:735-40. [PMID: 28549744 DOI: 10.1016/j.hpb.2017.04.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
413 Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer 2017;123:1979-88. [PMID: 28192597 DOI: 10.1002/cncr.30571] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 10.8] [Reference Citation Analysis]
414 Singh SK, Talwar R, Kannan N, Tyagi AK, Jaiswal P, Kumar A. Chemotherapy Compared with Best Supportive Care for Metastatic/Unresectable Gallbladder Cancer: a Non-randomized Prospective Cohort Study. Indian J Surg Oncol 2016;7:25-31. [PMID: 27065678 DOI: 10.1007/s13193-015-0443-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
415 Zaidi MY, Abou-Alfa GK, Ethun CG, Shrikhande SV, Goel M, Nervi B, Primrose J, Valle JW, Maithel SK. Evaluation and management of incidental gallbladder cancer. Chin Clin Oncol 2019;8:37. [PMID: 31431030 DOI: 10.21037/cco.2019.07.01] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
416 Shen ZT, Zhou H, Li AM, Li B, Shen JS, Zhu XX. Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma. Oncotarget. 2017;8:93541-93550. [PMID: 29212171 DOI: 10.18632/oncotarget.19972] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
417 Gao Y, Wang Z, Zhu Y, Zhu Q, Yang Y, Jin Y, Zhang F, Jiang L, Ye Y, Li H, Zhang Y, Liang H, Xiang S, Miao H, Liu Y, Hao Y. NOP2/Sun RNA methyltransferase 2 promotes tumor progression via its interacting partner RPL6 in gallbladder carcinoma. Cancer Sci 2019;110:3510-9. [PMID: 31487418 DOI: 10.1111/cas.14190] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
418 Fisher AV, Ronnekleiv-kelly SM. Surgical Management of Hilar Cholangiocarcinoma. Curr Surg Rep 2018;6. [DOI: 10.1007/s40137-018-0210-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
419 Park JO, Oh DY, Hsu C, Chen JS, Chen LT, Orlando M, Kim JS, Lim HY. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat 2015;47:343-61. [PMID: 25989801 DOI: 10.4143/crt.2014.308] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
420 Lee SH, Lee HS, Lee SH, Woo SM, Kim DU, Bang S. Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study. J Clin Med 2020;9:E1769. [PMID: 32517311 DOI: 10.3390/jcm9061769] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
421 Gou M, Zhang Y, Liu T, Si H, Wang Z, Yan H, Qian N, Dai G. PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis. Front Oncol 2021;11:648068. [PMID: 34221968 DOI: 10.3389/fonc.2021.648068] [Reference Citation Analysis]
422 Reduzzi C, Vismara M, Silvestri M, Celio L, Niger M, Peverelli G, De Braud F, Daidone MG, Cappelletti V. A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer.Int J Cancer. 2020;146:3495-3503. [PMID: 31814120 DOI: 10.1002/ijc.32822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
423 Braconi C, Patel T. Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am. 2010;24:871-84, vii. [PMID: 20937455 DOI: 10.1016/j.idc.2010.07.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
424 Jolissaint JS, Soares KC, Seier KP, Kundra R, Gönen M, Shin PJ, Boerner T, Sigel C, Madupuri R, Vakiani E, Cercek A, Harding JJ, Kemeny NE, Connell LC, Balachandran VP, D'Angelica MI, Drebin JA, Kingham TP, Wei AC, Jarnagin WR. Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. Clin Cancer Res 2021;27:4101-8. [PMID: 33963001 DOI: 10.1158/1078-0432.CCR-21-0412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
425 Ulusakarya A, Karaboué A, Ciacio O, Pittau G, Haydar M, Biondani P, Gumus Y, Chebib A, Almohamad W, Innominato PF. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer 2020;20:515. [PMID: 32493242 DOI: 10.1186/s12885-020-07004-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
426 Bekric D, Neureiter D, Ritter M, Jakab M, Gaisberger M, Pichler M, Kiesslich T, Mayr C. Long Non-Coding RNAs in Biliary Tract Cancer-An Up-to-Date Review. J Clin Med 2020;9:E1200. [PMID: 32331331 DOI: 10.3390/jcm9041200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
427 Loosen SH, Breuer A, Tacke F, Kather JN, Gorgulho J, Alizai PH, Bednarsch J, Roeth AA, Lurje G, Schmitz SM, Brozat JF, Paffenholz P, Vucur M, Ritz T, Koch A, Trautwein C, Ulmer TF, Roderburg C, Longerich T, Neumann UP, Luedde T. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer. JHEP Rep 2020;2:100080. [PMID: 32140677 DOI: 10.1016/j.jhepr.2020.100080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
428 Blechacz B. Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017;11:13-26. [PMID: 27928095 DOI: 10.5009/gnl15568] [Cited by in Crossref: 160] [Cited by in F6Publishing: 150] [Article Influence: 32.0] [Reference Citation Analysis]
429 Wang Y, Dong B, Xue W, Feng Y, Yang C, Liu P, Cao J, Zhu C. Anticancer Effect of Radix Astragali on Cholangiocarcinoma In Vitro and Its Mechanism via Network Pharmacology. Med Sci Monit 2020;26:e921162. [PMID: 32246704 DOI: 10.12659/MSM.921162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
430 Simbolo M, Vicentini C, Ruzzenente A, Brunelli M, Conci S, Fassan M, Mafficini A, Rusev B, Corbo V, Capelli P, Bria E, Pedron S, Turri G, Lawlor RT, Tortora G, Bassi C, Guglielmi A, Scarpa A. Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Sci Rep. 2018;8:7119. [PMID: 29740198 DOI: 10.1038/s41598-018-25669-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
431 Li X, Gao L, Zhang L, Sun H, Gou H. Third-line sunitinib treatment in a VHL-mutated metastatic intrahepatic cholangiocarcinoma: a case report and literature review. Cancer Biol Ther 2020;21:785-9. [PMID: 32552305 DOI: 10.1080/15384047.2020.1769418] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
432 Ciombor KK, Goff LW. Current therapy and future directions in biliary tract malignancies. Curr Treat Options Oncol 2013;14:337-49. [PMID: 23686724 DOI: 10.1007/s11864-013-0237-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
433 Vogel A, Saborowski A. Current and Future Systemic Therapies in Biliary Tract Cancer. Visc Med 2021;37:32-8. [PMID: 33708816 DOI: 10.1159/000513969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
434 Mayr C, Wagner A, Loeffelberger M, Bruckner D, Jakab M, Berr F, Di Fazio P, Ocker M, Neureiter D, Pichler M. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget. 2016;7:745-758. [PMID: 26623561 DOI: 10.18632/oncotarget.6378] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
435 Jiang L, He A, He X, Tao C. MicroRNA-126 enhances the sensitivity of osteosarcoma cells to cisplatin and methotrexate. Oncol Lett 2015;10:3769-78. [PMID: 26788206 DOI: 10.3892/ol.2015.3790] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
436 Yoon J, Kang SY, Lee KH, Cheon GJ, Oh DY. Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer. Cancer Res Treat 2021;53:471-9. [PMID: 33091966 DOI: 10.4143/crt.2020.577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
437 Baak R, Willemssen FEJA, van Norden Y, Eskens FALM, Milder MTW, Heijmen BJM, Koerkamp BG, Sprengers D, van Driel LMJW, Klümpen HJ, den Toom W, Koedijk MS, IJzermans JNM, Méndez Romero A. Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study. Cancers (Basel) 2021;13:3991. [PMID: 34439146 DOI: 10.3390/cancers13163991] [Reference Citation Analysis]
438 Cho S, Park I, Kim H, Jeong MS, Lim M, Lee ES, Kim JH, Kim S, Hong HJ. Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM. MAbs 2016;8:414-25. [PMID: 26785809 DOI: 10.1080/19420862.2015.1125067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
439 Overman MJ, Zhang J, Kopetz S, Davies M, Jiang ZQ, Stemke-Hale K, Rümmele P, Pilarsky C, Grützmann R, Hamilton S. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One. 2013;8:e65144. [PMID: 23776447 DOI: 10.1371/journal.pone.0065144] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
440 Manekeller S, Kalff JC. [Treatment approach for gall bladder and extrahepatic bile duct cancer]. Chirurg 2018;89:880-6. [PMID: 30094707 DOI: 10.1007/s00104-018-0704-4] [Reference Citation Analysis]
441 Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014;110:2165-2169. [PMID: 24714745 DOI: 10.1038/bjc.2014.190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
442 Potkonjak M, Miura JT, Turaga KK, Johnston FM, Tsai S, Christians KK, Gamblin TC. Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. HPB (Oxford) 2015;17:1119-23. [PMID: 26374242 DOI: 10.1111/hpb.12504] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
443 Juntermanns B, Fingas CD, Sotiropoulos GC, Jaradat D, Dechêne A, Reis H, Kasper S, Paul A, Kaiser GM. [Klatskin tumor: long-term survival following surgery]. Chirurg 2016;87:514-9. [PMID: 27090415 DOI: 10.1007/s00104-016-0169-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
444 Wu CD, Lee JC, Wu HC, Lee CW, Lin CF, Hsu MC, Lin CT. Preclinical verification of the efficacy by targeting peptide-linked liposomal nanoparticles for hepatocellular carcinoma therapy. Nanobiomedicine (Rij) 2019;6:1849543519880762. [PMID: 31908670 DOI: 10.1177/1849543519880762] [Reference Citation Analysis]
445 Kim NI, Noh MG, Kim JH, Won EJ, Lee YJ, Hur Y, Moon KS, Lee KH, Lee JH. Frequency and Prognostic Value of IDH Mutations in Korean Patients With Cholangiocarcinoma. Front Oncol 2020;10:1514. [PMID: 33014795 DOI: 10.3389/fonc.2020.01514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
446 Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. Cancer. 2019;125:4426-4434. [PMID: 31454426 DOI: 10.1002/cncr.32463] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
447 Medin CR, Maithel SK. Neoadjuvant therapy trials in biliary tract malignancies. J Surg Oncol 2022;125:84-8. [PMID: 34897705 DOI: 10.1002/jso.26714] [Reference Citation Analysis]
448 Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, Frega G, Barbera MA, de Lorenzo S, Garajova I, Di Marco M, Pinna AD, Cescon M, Cucchetti A, Ercolani G, D'Errico-Grigioni A, Pantaleo MA, Biasco G, Tavolari S; G.I.CO. (Gruppo Italiano Colangiocarcinoma). Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. Oncologist 2016;21:600-7. [PMID: 27032872 DOI: 10.1634/theoncologist.2015-0356] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
449 Sugihara T, Isomoto H, Gores G, Smoot R. YAP and the Hippo pathway in cholangiocarcinoma. J Gastroenterol 2019;54:485-91. [PMID: 30815737 DOI: 10.1007/s00535-019-01563-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
450 Sorscher S. Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab. Cancer Manag Res. 2013;9:1-3. [PMID: 24376362 DOI: 10.2147/cmar.s55091] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
451 Sugiura T, Uesaka K, Okamura Y, Ito T, Yamamoto Y, Ashida R, Ohgi K, Asakura H, Todaka A, Fukutomi A. Adjuvant chemoradiotherapy for positive hepatic ductal margin on cholangiocarcinoma. Ann Gastroenterol Surg 2020;4:455-63. [PMID: 32724890 DOI: 10.1002/ags3.12345] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
452 Liu H, Qiu G, Hu F, Wu H. Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection. World J Surg Oncol 2021;19:218. [PMID: 34284775 DOI: 10.1186/s12957-021-02330-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
453 Inoue M, Hakoda K, Sawada H, Hotta R, Ohmori I, Miyamoto K, Toyota K, Sadamoto S, Takahashi T. Locally advanced gallbladder cancer treated with effective chemotherapy and subsequent curative resection: a case report. J Med Case Rep 2022;16:30. [PMID: 35039070 DOI: 10.1186/s13256-021-03248-9] [Reference Citation Analysis]
454 Winter H, Kaisaki PJ, Harvey J, Giacopuzzi E, Ferla MP, Pentony MM, Knight SJL, Sharma RA, Taylor JC, McCullagh JSO. Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2019;11:E1895. [PMID: 31795195 DOI: 10.3390/cancers11121895] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
455 Yarchoan M, Cope L, Ruggieri AN, Anders RA, Noonan AM, Goff LW, Goyal L, Lacy J, Li D, Patel AK, He AR, Abou-Alfa GK, Spencer K, Kim EJ, Davis SL, McRee AJ, Kunk PR, Goyal S, Liu Y, Dennison L, Xavier S, Mohan AA, Zhu Q, Wang-Gillam A, Poklepovic A, Chen HX, Sharon E, Lesinski GB, Azad NS. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest 2021;131:e152670. [PMID: 34907910 DOI: 10.1172/JCI152670] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
456 Zhao X, Zhang C, Zhou H, Xiao B, Cheng Y, Wang J, Yao F, Duan C, Chen R, Liu Y, Feng C, Li H, Li J, Dai R. Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells. Oncotarget 2016;7:85492-501. [PMID: 27863431 DOI: 10.18632/oncotarget.13408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
457 Kuga D, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Long-term survival after multidisciplinary therapy for residual gallbladder cancer with peritoneal dissemination: a case report. Surg Case Rep 2017;3:76. [PMID: 28616794 DOI: 10.1186/s40792-017-0351-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
458 Yoo C, Shin SH, Park JO, Kim KP, Jeong JH, Ryoo BY, Lee W, Song KB, Hwang DW, Park JH, Lee JH. Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. Cancers (Basel) 2021;13:1647. [PMID: 33916008 DOI: 10.3390/cancers13071647] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
459 Yamamoto M, Ariizumi S. Surgical outcomes of intrahepatic cholangiocarcinoma. Surg Today. 2011;41:896-902. [PMID: 21748603 DOI: 10.1007/s00595-011-4517-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
460 Takayoshi K, Sagara K, Uchino K, Kusaba H, Sakamoto N, Iguchi A, Baba E. A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine. BMC Cancer 2015;15:426. [PMID: 26001650 DOI: 10.1186/s12885-015-1443-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
461 Chen Y, Liu H, Zhang J, Wu Y, Zhou W, Cheng Z, Lou J, Zheng S, Bi X, Wang J, Guo W, Li F, Wang J, Zheng Y, Li J, Cheng S, Zeng Y, Liu J. Prognostic value and predication model of microvascular invasion in patients with intrahepatic cholangiocarcinoma: a multicenter study from China. BMC Cancer 2021;21:1299. [PMID: 34863147 DOI: 10.1186/s12885-021-09035-5] [Reference Citation Analysis]
462 Chen Y, Li H, Jiang X, Chen D, Ni J, Sun H, Luo J, Yao H, Xu L. Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study.Eur Radiol. 2016;26:3500-3509. [PMID: 26822373 DOI: 10.1007/s00330-016-4208-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
463 Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J. miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res. 2013;73:6435-6447. [PMID: 23950211 DOI: 10.1158/0008-5472.can-12-3308] [Cited by in Crossref: 87] [Cited by in F6Publishing: 68] [Article Influence: 9.7] [Reference Citation Analysis]
464 Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Res 2016;76:4775-84. [PMID: 27328733 DOI: 10.1158/0008-5472.CAN-16-0188] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
465 Buettner S, Ten Cate DWG, Bagante F, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, Margonis GA, Weiss M, Bauer TW, Shen F, Poultsides GA, Marsh JW, IJzermans JNM, Pawlik TM, Koerkamp BG. Survival after Resection of Multiple Tumor Foci of Intrahepatic Cholangiocarcinoma. J Gastrointest Surg 2019;23:2239-46. [PMID: 30887301 DOI: 10.1007/s11605-019-04184-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
466 Joechle K, Guenzle J, Hellerbrand C, Strnad P, Cramer T, Neumann UP, Lang SA. Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer. World J Gastrointest Oncol 2021; 13(11): 1632-1647 [PMID: 34853640 DOI: 10.4251/wjgo.v13.i11.1632] [Reference Citation Analysis]
467 Takenami T, Maeda S, Karasawa H, Suzuki T, Furukawa T, Morikawa T, Takadate T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Unno M. Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis. BMC Cancer 2019;19:318. [PMID: 30953499 DOI: 10.1186/s12885-019-5548-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
468 Kanthan R, Senger JL, Ahmed S, Kanthan SC. Gallbladder Cancer in the 21st Century. J Oncol. 2015;2015:967472. [PMID: 26421012 DOI: 10.1155/2015/967472] [Cited by in Crossref: 106] [Cited by in F6Publishing: 111] [Article Influence: 15.1] [Reference Citation Analysis]
469 Chang PM, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Liu CY, Chen MH, Chen MH, Yeh CN. Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. Oncol Lett. 2018;16:566-572. [PMID: 29963132 DOI: 10.3892/ol.2018.8690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
470 Mazloom A, Ghalehsari N, Gazivoda V, Nimkar N, Paul S, Gregos P, Rateshwar J, Khan U. Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. J Clin Med 2020;9:E2533. [PMID: 32781500 DOI: 10.3390/jcm9082533] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
471 Gringeri E, Gambato M, Sapisochin G, Ivanics T, Lynch EN, Mescoli C, Burra P, Cillo U, Russo FP. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. J Clin Med 2020;9:E1353. [PMID: 32380750 DOI: 10.3390/jcm9051353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
472 Wheatley RC, Kilgour E, Jacobs T, Lamarca A, Hubner RA, Valle JW, McNamara MG. Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. Br J Cancer 2021. [PMID: 34663949 DOI: 10.1038/s41416-021-01583-8] [Reference Citation Analysis]
473 Li Q, Zhan M, Chen W, Zhao B, Yang K, Yang J, Yi J, Huang Q, Mohan M, Hou Z, Wang J. Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1. Oncotarget 2016;7:10271-82. [PMID: 26848531 DOI: 10.18632/oncotarget.7171] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
474 Romiti A, D’Antonio C, Zullo A, Sarcina I, Di Rocco R, Barucca V, Durante V, Marchetti P. Chemotherapy for the biliary tract cancers: moving toward improved survival time. J Gastrointest Cancer. 2012;43:396-404. [PMID: 22328060 DOI: 10.1007/s12029-012-9369-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
475 Uenishi T, Yamamoto T, Takemura S, Kubo S. Surgical treatment for intrahepatic cholangiocarcinoma. Clin J Gastroenterol 2014;7:87-93. [PMID: 26183622 DOI: 10.1007/s12328-014-0460-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
476 Popp FC, Weigt J, Kalinski T, Betzler C, Arend J, Garlipp B, Benckert C, Bruns CJ. [Papillary tumors - therapeutic concepts]. Chirurg 2015;86:811-22. [PMID: 26223666 DOI: 10.1007/s00104-015-0048-2] [Reference Citation Analysis]
477 Fornaro L, Vivaldi C, Cereda S, Leone F, Aprile G, Lonardi S, Silvestris N, Santini D, Milella M, Caparello C, Musettini G, Pasquini G, Falcone A, Brandi G, Sperduti I, Vasile E; GICO group (Gruppo Italiano COlangiocarcinoma). Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. J Exp Clin Cancer Res. 2015;34:156. [PMID: 26693938 DOI: 10.1186/s13046-015-0267-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
478 Zhang R, Li Y, Dong X, Peng L, Nie X. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer. Med Oncol. 2014;31:347. [PMID: 25416050 DOI: 10.1007/s12032-014-0347-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
479 Samatiwat P, Tabtimmai L, Suphakun P, Jiwacharoenchai N, Toviwek B, Kukongviriyapan V, Gleeson MP, Choowongkomon K. The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines. Asian Pac J Cancer Prev 2021;22:381-90. [PMID: 33639651 DOI: 10.31557/APJCP.2021.22.2.381] [Reference Citation Analysis]
480 Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN; Cancer Genome Atlas Network. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep 2017;19:2878-80. [PMID: 28658632 DOI: 10.1016/j.celrep.2017.06.008] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 16.4] [Reference Citation Analysis]
481 Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis 2013;34:725-38. [PMID: 23455378 DOI: 10.1093/carcin/bgt086] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 6.8] [Reference Citation Analysis]
482 Yamashita YI, Shirabe K, Beppu T, Eguchi S, Nanashima A, Ohta M, Ueno S, Kondo K, Kitahara K, Shiraishi M, Takami Y, Noritomi T, Okamoto K, Ogura Y, Baba H, Fujioka H. Surgical management of recurrent intrahepatic cholangiocarcinoma: predictors, adjuvant chemotherapy, and surgical therapy for recurrence: A multi-institutional study by the Kyushu Study Group of Liver Surgery. Ann Gastroenterol Surg 2017;1:136-42. [PMID: 29863136 DOI: 10.1002/ags3.12018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
483 Shimizu S, Oshita A, Tashiro H, Amano H, Kobayashi T, Tanaka M, Arihiro K, Ohdan H. Synchronous double cancers of primary hepatic adenosquamous carcinoma and hepatocellular carcinoma: report of a case. Surg Today 2013;43:418-23. [PMID: 23014833 DOI: 10.1007/s00595-012-0346-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
484 May M, Raufi AG, Sadeghi S, Chen K, Iuga A, Sun Y, Ahmed F, Bates S, Manji GA. Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature. Oncologist 2021;26:640-6. [PMID: 33896096 DOI: 10.1002/onco.13800] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Fujiwara Y, Kobayashi S, Nagano H, Kanai M, Hatano E, Toyoda M, Ajiki T, Takashima Y, Yoshimura K, Hamada A, Minami H, Ioka T. Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101). PLoS One 2015;10:e0143072. [PMID: 26633034 DOI: 10.1371/journal.pone.0143072] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
486 Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 2013;4:156-65. [PMID: 23391555 DOI: 10.18632/oncotarget.832] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
487 Morton SD, Cadamuro M, Brivio S, Vismara M, Stecca T, Massani M, Bassi N, Furlanetto A, Joplin RE, Floreani A, Fabris L, Strazzabosco M. Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation. Oncotarget 2015;6:26052-64. [PMID: 26296968 DOI: 10.18632/oncotarget.4482] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
488 Tshering G, Dorji PW, Chaijaroenkul W, Na-Bangchang K. Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review. Am J Trop Med Hyg. 2018;98:1788-1797. [PMID: 29637880 DOI: 10.4269/ajtmh.17-0879] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
489 Lee C, Ryu HW, Kim S, Kim M, Oh SR, Ahn KS, Park J. Verminoside from Pseudolysimachion rotundum var. subintegrum sensitizes cisplatin-resistant cancer cells and suppresses metastatic growth of human breast cancer. Sci Rep 2020;10:20337. [PMID: 33230126 DOI: 10.1038/s41598-020-77401-7] [Reference Citation Analysis]
490 Kim ST, Jang KT, Lee J, Jang HM, Choi HJ, Jang HL, Park SH, Park YS, Lim HY, Kang WK, Park JO. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. Transl Oncol 2015;8:40-6. [PMID: 25749176 DOI: 10.1016/j.tranon.2014.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
491 Pietge H, Sánchez-Velázquez P, Akhoundova D, Siebenhüner A, Winder T, Bachmann H, Nguyen-Kim TDL, Breitenstein S, Knuth A, Petrowsky H, Pestalozzi B, Clavien PA, Samaras P. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study. Oncology 2021;99:300-9. [PMID: 33657549 DOI: 10.1159/000512967] [Reference Citation Analysis]
492 Loosen SH, Benz F, Niedeggen J, Schmeding M, Schüller F, Koch A, Vucur M, Tacke F, Trautwein C, Roderburg C, Neumann UP, Luedde T. Serum levels of S100A6 are unaltered in patients with resectable cholangiocarcinoma. Clin Transl Med 2016;5:39. [PMID: 27709523 DOI: 10.1186/s40169-016-0120-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
493 Maeda O, Ebata T, Shimokata T, Matsuoka A, Inada-Inoue M, Morita S, Takano Y, Urakawa H, Miyai Y, Sugishita M, Mitsuma A, Ando M, Mizuno T, Nagino M, Ando Y. Chemotherapy for biliary tract cancer: real-world experience in a single institute. Nagoya J Med Sci 2020;82:725-33. [PMID: 33311803 DOI: 10.18999/nagjms.82.4.725] [Reference Citation Analysis]
494 Ma L, Qiu J, Zhang Y, Qiu T, Wang B, Chen W, Li X, Sun J, Wang K, Li X, Gu Y, Shu Y, Chen X. Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase, a strong association with survival. Onco Targets Ther 2018;11:2533-43. [PMID: 29765232 DOI: 10.2147/OTT.S150502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
495 Klose J, Guerlevik E, Trostel T, Kühnel F, Schmidt T, Schneider M, Ulrich A. Salinomycin inhibits cholangiocarcinoma growth by inhibition of autophagic flux. Oncotarget 2018;9:3619-30. [PMID: 29423070 DOI: 10.18632/oncotarget.23339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
496 Matsumoto T, Itoh S, Yoshizumi T, Kurihara T, Yoshiya S, Mano Y, Takeishi K, Harada N, Ikegami T, Soejima Y, Baba H, Mori M. C-reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma. BJS Open 2020. [PMID: 32959537 DOI: 10.1002/bjs5.50348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
497 Zafar S, Potdar R, Tiu A, Varadi G, Leighton J. Acute Left Internal Carotid Artery and Right Popliteal Artery Occlusion Related to Cisplatin-Gemcitabine Based Chemotherapy. Case Rep Neurol Med 2018;2018:9281918. [PMID: 30652037 DOI: 10.1155/2018/9281918] [Reference Citation Analysis]
498 Liu HT, Cheng SB, Lai CY, Chen YJ, Su TC, Wu CC. Locoregional therapies in patients with recurrent intrahepatic cholangiocarcinoma after curative resection. Therap Adv Gastroenterol 2020;13:1756284820976974. [PMID: 33354228 DOI: 10.1177/1756284820976974] [Reference Citation Analysis]
499 Mcgrath NA, Fu J, Gu SZ, Xie C. Targeting cancer stem cells in cholangiocarcinoma (Review). Int J Oncol 2020;57:397-408. [PMID: 32468022 DOI: 10.3892/ijo.2020.5074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
500 Cereda S, Belli C, Reni M. Adjuvant treatment in biliary tract cancer: To treat or not to treat? World J Gastroenterol 2012; 18(21): 2591-2596 [PMID: 22690066 DOI: 10.3748/wjg.v18.i21.2591] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
501 Wang J, Loeuillard E, Gores GJ, Ilyas SI. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells? Expert Opin Ther Targets 2021;25:835-45. [PMID: 34806500 DOI: 10.1080/14728222.2021.2010046] [Reference Citation Analysis]
502 Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 2017;18:2780-2794. [PMID: 28297679 DOI: 10.1016/j.celrep.2017.02.033] [Cited by in Crossref: 194] [Cited by in F6Publishing: 185] [Article Influence: 38.8] [Reference Citation Analysis]
503 Huang XH, Jiang Y, Lv LZ, Hu HZ. Long-term tumor-free survival after cyst excision plus pancreaticoduodenectomy for the treatment of congenital choledochal cyst with malignant change. Asian J Surg 2021;44:1476-8. [PMID: 34404599 DOI: 10.1016/j.asjsur.2021.07.072] [Reference Citation Analysis]
504 Erdmann JI, Morak MJ, Duivenvoorden HJ, van Dekken H, Kazemier G, Kok NF, van Eijck CH. Long-term survival after resection for non-pancreatic periampullary cancer followed by adjuvant intra-arterial chemotherapy and concomitant radiotherapy. HPB (Oxford) 2015;17:573-9. [PMID: 25800041 DOI: 10.1111/hpb.12401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
505 Satyananda V, Chouliaras K, Cherkassky L, Schwarz RE. A case from the future of HPB surgical oncology: resection of biliary tract cancer after immunotherapy. J Surg Case Rep 2021;2021:rjab414. [PMID: 34729163 DOI: 10.1093/jscr/rjab414] [Reference Citation Analysis]
506 Ma WW, Zhu M, Lam ET, Diamond JR, Dy GK, Fisher GA, Goff LW, Alberts S, Bui LA, Sanghal A, Kothekar M, Khopade A, Chimote G, Faulkner R, Eckhardt SG, Adjei AA, Jimeno A. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. Cancer Chemother Pharmacol 2021;87:779-88. [PMID: 33634324 DOI: 10.1007/s00280-021-04235-z] [Reference Citation Analysis]
507 Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol 2016;7:819-27. [PMID: 28078106 DOI: 10.21037/jgo.2016.11.11] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
508 Yoshikawa N, Saito Y, Manabe H, Nakaoka T, Uchida R, Furukawa R, Muramatsu T, Sugiyama Y, Kimura M, Saito H. Glucose Depletion Enhances the Stem Cell Phenotype and Gemcitabine Resistance of Cholangiocarcinoma Organoids through AKT Phosphorylation and Reactive Oxygen Species. Cancers (Basel) 2019;11:E1993. [PMID: 31835877 DOI: 10.3390/cancers11121993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
509 Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21(7): 2096-2101 [PMID: 25717243 DOI: 10.3748/wjg.v21.i7.2096] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
510 Zou L, Li X, Wu X, Cui J, Cui X, Song X, Ren T, Han X, Zhu Y, Li H, Wu W, Wang X, Gong W, Wang L, Li M, Lau WY, Liu Y. Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study. BMC Cancer 2021;21:818. [PMID: 34266407 DOI: 10.1186/s12885-021-08549-2] [Reference Citation Analysis]
511 Kaiho T, Suzuki H, Yamamoto T, Morimoto J, Sakairi Y, Wada H, Nakajima T, Yoshino I. Surgical outcomes of pulmonary metastasis from hepatopancreatobiliary carcinomas: a comparison with pulmonary metastasis from colorectal carcinomas. Surg Today 2019;49:762-8. [PMID: 30859309 DOI: 10.1007/s00595-019-01794-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
512 Hirata H, Kuwatani M, Nakajima K, Kodama Y, Yoshikawa Y, Ogawa M, Sakamoto N. Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes. Cancer Sci 2021;112:828-38. [PMID: 33345417 DOI: 10.1111/cas.14780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
513 Bednarsch J, Czigany Z, Lurje I, Strnad P, Bruners P, Ulmer TF, den Dulk M, Lurje G, Neumann UP. The role of ALPPS in intrahepatic cholangiocarcinoma. Langenbecks Arch Surg 2019;404:885-94. [PMID: 31734715 DOI: 10.1007/s00423-019-01838-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
514 Wintheiser G, Zemla T, Shi Q, Tran N, Prasai K, Tella SH, Mody K, Ahn D, Borad M, Bekaii-Saab T, Mahipal A. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. JCO Precis Oncol 2022;6:e2100156. [PMID: 35005992 DOI: 10.1200/PO.21.00156] [Reference Citation Analysis]
515 Massironi S, Pilla L, Elvevi A, Longarini R, Rossi RE, Bidoli P, Invernizzi P. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. Cells 2020;9:E688. [PMID: 32168869 DOI: 10.3390/cells9030688] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
516 Chiang NJ, Chen MH, Yang SH, Hsu C, Yen CJ, Tsou HH, Su YY, Chen JS, Shan YS, Chen LT. Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study. Liver Int 2020;40:2535-43. [PMID: 32463975 DOI: 10.1111/liv.14538] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
517 Xie C, McGrath NA, Monge Bonilla C, Fu J. Systemic treatment options for advanced biliary tract carcinoma. J Gastroenterol 2020;55:944-57. [PMID: 32748173 DOI: 10.1007/s00535-020-01712-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
518 Kemeny NE, Schwartz L, Gönen M, Yopp A, Gultekin D, D'Angelica MI, Fong Y, Haviland D, Gewirtz AN, Allen P, Jarnagin WR. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology 2011;80:153-9. [PMID: 21677464 DOI: 10.1159/000324704] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
519 Zou Y, Li R, Kuang D, Zuo M, Li W, Tong W, Jiang L, Zhou M, Chen Y, Gong W, Liu L, Tou F. Galangin Inhibits Cholangiocarcinoma Cell Growth and Metastasis through Downregulation of MicroRNA-21 Expression. Biomed Res Int 2020;2020:5846938. [PMID: 32626749 DOI: 10.1155/2020/5846938] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
520 Xiao JB, Weng JY, Hu YY, Deng GL, Wan XJ. Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma. World J Gastroenterol 2020; 26(31): 4589-4606 [PMID: 32884219 DOI: 10.3748/wjg.v26.i31.4589] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
521 Andersen JB, Thorgeirsson SS. A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepat Oncol 2014;1:143-57. [PMID: 24772266 DOI: 10.2217/hep.13.4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
522 Toyoda M, Ajiki T, Fujiwara Y, Nagano H, Kobayashi S, Sakai D, Hatano E, Kanai M, Nakamori S, Miyamoto A. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004). Cancer Chemother Pharmacol. 2014;73:1295-1301. [PMID: 24614947 DOI: 10.1007/s00280-014-2431-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
523 Yoo KH, Kim NK, Kwon WI, Lee C, Kim SY, Jang J, Ahn J, Kang M, Jang H, Kim ST, Ahn S, Jang KT, Park YS, Park WY, Lee J, Heo JS, Park JO. Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. Transl Oncol 2016;9:173-8. [PMID: 27267833 DOI: 10.1016/j.tranon.2016.01.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
524 Lowery MA, Burris HA 3rd, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol 2019;4:711-20. [PMID: 31300360 DOI: 10.1016/S2468-1253(19)30189-X] [Cited by in Crossref: 69] [Cited by in F6Publishing: 33] [Article Influence: 23.0] [Reference Citation Analysis]
525 Saluja SS, Nekarakanti PK, Mishra PK, Srivastava A, Singh K. Prospective Randomized Controlled Trial Comparing Adjuvant Chemotherapy vs. No Chemotherapy for Patients with Carcinoma of Gallbladder Undergoing Curative Resection. J Gastrointest Surg 2021. [PMID: 34545545 DOI: 10.1007/s11605-021-05143-6] [Reference Citation Analysis]
526 Inchingolo R, Acquafredda F, Ferraro V, Laera L, Surico G, Surgo A, Fiorentino A, Marini S, de'Angelis N, Memeo R, Spiliopoulos S. Non-surgical treatment of hilar cholangiocarcinoma. World J Gastrointest Oncol 2021; 13(11): 1696-1708 [PMID: 34853644 DOI: 10.4251/wjgo.v13.i11.1696] [Reference Citation Analysis]
527 Ebata T, Ercolani G, Alvaro D, Ribero D, Di Tommaso L, Valle JW. Current Status on Cholangiocarcinoma and Gallbladder Cancer. Liver Cancer. 2016;6:59-65. [PMID: 27995089 DOI: 10.1159/000449493] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
528 Gamboa AC, Maithel SK. The Landmark Series: Gallbladder Cancer. Ann Surg Oncol 2020;27:2846-58. [PMID: 32474816 DOI: 10.1245/s10434-020-08654-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
529 Bednarsch J, Kather J, Tan X, Sivakumar S, Cacchi C, Wiltberger G, Czigany Z, Ulmer F, Neumann UP, Heij LR. Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma. Liver Cancer 2021;10:260-74. [PMID: 34239812 DOI: 10.1159/000515303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
530 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
531 Watanabe A, Kida M, Miyazawa S, Iwai T, Okuwaki K, Kaneko T, Yamauchi H, Takezawa M, Imaizumi H, Koizumi W. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer. World J Gastroenterol 2015; 21(19): 5979-5984 [PMID: 26019463 DOI: 10.3748/wjg.v21.i19.5979] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
532 Urban O, Vanek P, Zoundjiekpon V, Falt P. Endoscopic Perspective in Cholangiocarcinoma Diagnostic Process. Gastroenterol Res Pract 2019;2019:9704870. [PMID: 31933635 DOI: 10.1155/2019/9704870] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
533 Lee DW, Im SA, Kim YJ, Yang Y, Rhee J, Na II, Lee KH, Kim TY, Han SW, Choi IS, Oh DY, Kim JH, Kim TY, Bang YJ. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy. Cancer Res Treat 2017;49:807-15. [PMID: 28111425 DOI: 10.4143/crt.2016.326] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
534 Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res Commun 2021;27:100356. [PMID: 33799004 DOI: 10.1016/j.ctarc.2021.100356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
535 Nishiguchi R, Kim DH, Honda M, Sakamoto T. Squamous cell carcinoma of the extrahepatic bile duct with metachronous para-aortic lymph node metastasis successfully treated with S-1 plus cisplatin. BMJ Case Rep 2016;2016:bcr2016218177. [PMID: 27932438 DOI: 10.1136/bcr-2016-218177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
536 Canale M, Monti M, Rapposelli IG, Ulivi P, Sullo FG, Bartolini G, Tiberi E, Frassineti GL. Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer. Cancers (Basel) 2021;13:5671. [PMID: 34830826 DOI: 10.3390/cancers13225671] [Reference Citation Analysis]
537 Feng K, Liu Y, Zhao Y, Yang Q, Dong L, Liu J, Li X, Zhao Z, Mei Q, Han W. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J Immunother Cancer 2020;8:e000367. [PMID: 32487569 DOI: 10.1136/jitc-2019-000367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
538 Kirstein MM, Vogel A. Epidemiology and Risk Factors of Cholangiocarcinoma. Visc Med. 2016;32:395-400. [PMID: 28229073 DOI: 10.1159/000453013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 10.5] [Reference Citation Analysis]
539 Shao F, Qi W, Meng FT, Qiu L, Huang Q. Role of palliative radiotherapy in unresectable intrahepatic cholangiocarcinoma: population-based analysis with propensity score matching. Cancer Manag Res 2018;10:1497-506. [PMID: 29942151 DOI: 10.2147/CMAR.S160680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
540 Noguchi R, Yamaguchi K, Ikenoue T, Terakado Y, Ohta Y, Yamashita N, Kainuma O, Yokoi S, Maru Y, Nagase H, Furukawa Y. Genetic alterations in Japanese extrahepatic biliary tract cancer. Oncol Lett 2017;14:877-84. [PMID: 28693246 DOI: 10.3892/ol.2017.6224] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
541 Wang J, Bo X, Nan L, Wang CC, Gao Z, Suo T, Ni X, Liu H, Lu P, Wang Y, Liu H. Landscape of distant metastasis mode and current chemotherapy efficacy of the advanced biliary tract cancer in the United States, 2010-2016. Cancer Med 2020;9:1335-48. [PMID: 31876990 DOI: 10.1002/cam4.2794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
542 Kim ST, Oh SY, Lee J, Kang JH, Lee HW, Lee MA, Sohn BS, Hong JH, Park YS, Park JO, Lim HY. Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. J Cancer 2019;10:6185-90. [PMID: 31772650 DOI: 10.7150/jca.37610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
543 Dreyer C, Sablin MP, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S. Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol 2015; 7(6): 910-915 [PMID: 25937868 DOI: 10.4254/wjh.v7.i6.910] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
544 Laoveeravat P, Jaruvongvanich V, Wongjarupong N, Linlawan S, Tanpowpong N, Phathong C, Phatharacharukul P, Treeprasertsuk S, Rerknimitr R, Chaiteerakij R. Outcome and validation of a new clinically based staging system for predicting survival of perihilar cholangiocarcinoma patients. JGH Open 2017;1:56-61. [PMID: 30483535 DOI: 10.1002/jgh3.12009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
545 Perez-Montoyo H. Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma. Cells 2020;9:E614. [PMID: 32143356 DOI: 10.3390/cells9030614] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
546 Forsmark CE, Diniz AL, Zhu AX. Consensus conference on hilar cholangiocarcinoma. HPB (Oxford) 2015;17:666-8. [PMID: 26172133 DOI: 10.1111/hpb.12451] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
547 Peixoto RD, Renouf D, Lim H. A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol 2014;5:428-32. [PMID: 25436121 DOI: 10.3978/j.issn.2078-6891.2014.081] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
548 Leiting JL, Murphy SJ, Bergquist JR, Hernandez MC, Ivanics T, Abdelrahman AM, Yang L, Lynch I, Smadbeck JB, Cleary SP, Nagorney DM, Torbenson MS, Graham RP, Roberts LR, Gores GJ, Smoot RL, Truty MJ. Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine. JHEP Rep 2020;2:100068. [PMID: 32181445 DOI: 10.1016/j.jhepr.2020.100068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
549 Lee SJ, Kim JE, Kim ST, Lee J, Park SH, Park JO, Kang WK, Park YS, Lim HY. The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. Transl Oncol 2018;11:353-7. [PMID: 29448202 DOI: 10.1016/j.tranon.2018.01.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
550 Yamada M, Furukawa D, Yazawa N, Izumi H, Masuoka Y, Mashiko T, Kawaguchi Y, Ogawa M, Kawashima Y, Mine T, Hirabayashi K, Nakagohri T. Undifferentiated carcinoma of the ampulla of Vater. Surg Case Rep 2017;3:9. [PMID: 28063144 DOI: 10.1186/s40792-016-0284-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
551 He X, Zhu Y, Wang Y, Hao Y, Hong J. Advances in stent therapy for malignant biliary obstruction. Abdom Radiol (NY). 2021;46:351-361. [PMID: 32451676 DOI: 10.1007/s00261-020-02593-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
552 Martin SP, Ruff S, Diggs LP, Drake J, Ayabe RI, Brown ZJ, Wach MM, Steinberg SM, Davis JL, Hernandez JM. Tumor grade and sex should influence the utilization of portal lymphadenectomy for early stage intrahepatic cholangiocarcinoma. HPB (Oxford) 2019;21:419-24. [PMID: 30139566 DOI: 10.1016/j.hpb.2018.07.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
553 Regalla DKR, Jacob R, Manne A, Paluri RK. Therapeutic options for ampullary carcinomas. A review. Oncol Rev. 2019;13:440. [PMID: 31565197 DOI: 10.4081/oncol.2019.440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
554 Li G, Liu T, Zhang B, Chen W, Ding Z. Genome-wide identification of a competing endogenous RNA network in cholangiocarcinoma. J Cell Biochem. 2019;120:18995-19003. [PMID: 31270845 DOI: 10.1002/jcb.29222] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
555 Fiorentini G, Mambrini A, Sarti D, Cantore M, Mulazzani L, Mattioli GM, Guadagni S. Hepatic intra-arterial and systemic chemotherapy followed by maintenance therapy for the treatment of cholangiocarcinoma. Hepat Oncol 2017;4:45-53. [PMID: 30191053 DOI: 10.2217/hep-2017-0001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
556 Lieke T, Ramackers W, Bergmann S, Klempnauer J, Winkler M, Klose J. Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro. BMC Cancer 2012;12:466. [PMID: 23057720 DOI: 10.1186/1471-2407-12-466] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
557 Feng F, Cheng Q, Zhang D, Li B, Qin H, Xu C, Han M, Yu Y, Li Z, Li JY, Qiu Z, Xiong L, Liu C, Li F, Yi B, Jiang X. Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study. Oncol Rep 2020;43:1089-102. [PMID: 32323774 DOI: 10.3892/or.2020.7491] [Reference Citation Analysis]
558 Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, Ijzermans JNM, Vivarelli M, Zieniewicz K, Olde Damink SWM, Groot Koerkamp B. Surgery for cholangiocarcinoma. Liver Int 2019;39 Suppl 1:143-55. [PMID: 30843343 DOI: 10.1111/liv.14089] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 20.0] [Reference Citation Analysis]
559 Sung YN, Kim SJ, Jun SY, Yoo C, Kim KP, Lee JH, Hwang DW, Hwang S, Lee SS, Hong SM. Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma. Front Oncol 2021;11:658564. [PMID: 34367955 DOI: 10.3389/fonc.2021.658564] [Reference Citation Analysis]
560 Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer. Cancer Res Treat 2019;51:886-900. [PMID: 30282449 DOI: 10.4143/crt.2018.375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
561 Bian JL, Wang MM, Tong EJ, Sun J, Li M, Miao ZB, Li YL, Zhu BH, Xu JJ. Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation. World J Gastroenterol 2017; 23(23): 4311-4316 [PMID: 28694672 DOI: 10.3748/wjg.v23.i23.4311] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
562 Marquardt JU, Andersen JB. Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepat Oncol. 2015;2:79-93. [PMID: 26257864 DOI: 10.2217/hep.14.24] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
563 Fong ZV, Brownlee SA, Qadan M, Tanabe KK. The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. Ann Surg Oncol 2021;28:2660-74. [PMID: 33646431 DOI: 10.1245/s10434-021-09671-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
564 Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. J Exp Pharmacol 2021;13:303-28. [PMID: 33776489 DOI: 10.2147/JEP.S267383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
565 Ramaswamy A, Ostwal V, Pande N, Sahu A, Jandyal S, Ramadwar M, Shetty N, Patkar S, Goel M, Gupta S. Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option. J Gastrointest Cancer 2016;47:305-12. [PMID: 27211249 DOI: 10.1007/s12029-016-9828-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
566 Chen B, Zhou W, Zhao W, Yuan P, Tang C, Wang G, Leng J, Ma J, Wang X, Hui Y, Wang Q. Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling. Oncol Lett 2019;18:1989-98. [PMID: 31423269 DOI: 10.3892/ol.2019.10497] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
567 Paz-Fumagalli R, Core J, Padula C, Montazeri S, McKinney J, Frey G, Devcic Z, Lewis A, Ritchie C, Mody K, Krishnan S, Toskich B. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. Oncotarget 2021;12:2075-88. [PMID: 34611481 DOI: 10.18632/oncotarget.28060] [Reference Citation Analysis]
568 Hu Y, Wang J, Tao H, Wu B, Sun J, Cheng Y, Dong W, Li R. Increased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trials. PLoS One 2013;8:e74872. [PMID: 24086388 DOI: 10.1371/journal.pone.0074872] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
569 Mahnken AH. Current status of transarterial radioembolization. World J Radiol 2016; 8(5): 449-459 [PMID: 27247711 DOI: 10.4329/wjr.v8.i5.449] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
570 Xie Y, Wang Y, Li J, Hang Y, Jaramillo L, Wehrkamp CJ, Phillippi MA, Mohr AM, Chen Y, Talmon GA, Mott JL, Oupický D. Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness. Theranostics 2018;8:4305-20. [PMID: 30214622 DOI: 10.7150/thno.26506] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
571 Kocsis J, Árokszállási A, András C, Balogh I, Béres E, Déri J, Peták I, Jánváry L, Horváth Z. Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion. J Gastrointest Oncol 2017;8:E32-8. [PMID: 28480077 DOI: 10.21037/jgo.2017.01.06] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
572 Kus T, Aktas G, Kalender ME, Sevinc A, Camci C. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study. J Gastrointest Cancer 2017;48:170-5. [PMID: 27714651 DOI: 10.1007/s12029-016-9880-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
573 Pereira SP, Jitlal M, Duggan M, Lawrie E, Beare S, O'Donoghue P, Wasan HS, Valle JW, Bridgewater J, Ramage J, Przemioslo R, Hammonds R, Aithal G, Murphy F, Foster G, Sturgess R. PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. ESMO Open 2018;3:e000379. [PMID: 30094069 DOI: 10.1136/esmoopen-2018-000379] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
574 Kubota K, Hasegawa S, Iwasaki A, Sato T, Fujita Y, Hosono K, Nakajima A, Mori R, Matsuyama R, Endo I. Stent placement above the sphincter of Oddi permits implementation of neoadjuvant chemotherapy in patients with initially unresectable Klatskin tumor. Endosc Int Open 2016;4:E427-33. [PMID: 27092322 DOI: 10.1055/s-0042-102246] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
575 Fisher SB, Patel SH, Kooby DA, Weber S, Bloomston M, Cho C, Hatzaras I, Schmidt C, Winslow E, Staley CA 3rd, Maithel SK. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford). 2012;14:514-522. [PMID: 22762399 DOI: 10.1111/j.1477-2574.2012.00489.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
576 Nasrallah AA, Khachfe HH, Salhab HA, Fares MY, Fares J. Targeted Therapies in Trial for Non-Resectable Gallbladder Cancer. J Gastrointest Cancer 2021;52:515-22. [PMID: 32394022 DOI: 10.1007/s12029-020-00411-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
577 Galdy S, Lamarca A, McNamara MG, Hubner RA, Cella CA, Fazio N, Valle JW. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev 2017;36:141-57. [PMID: 27981460 DOI: 10.1007/s10555-016-9645-x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 12.6] [Reference Citation Analysis]
578 Wang C, Jing H, Sha D, Wang W, Chen J, Cui Y, Han J. HBV-associated intrahepatic cholangiocarcinoma with high serum alpha-fetoprotein: a case report with review of literature. BMC Infect Dis 2016;16:295. [PMID: 27301956 DOI: 10.1186/s12879-016-1643-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
579 Kai Y, Ikezawa K, Takada R, Daiku K, Maeda S, Abe Y, Yamai T, Fukutake N, Nakabori T, Uehara H, Nagata S, Wada H, Ohkawa K. Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer. JGH Open 2021;5:712-6. [PMID: 34124390 DOI: 10.1002/jgh3.12576] [Reference Citation Analysis]
580 Kobayashi S, Ueno M, Nagashima S, Sano Y, Kawano K, Fukushima T, Asama H, Tezuka S, Morimoto M. Association between time to stent dysfunction and the anti-tumour effect of systemic chemotherapy following stent placement in patients with pancreaticobiliary cancers and malignant gastric outlet obstruction: a retrospective cohort study. BMC Cancer 2021;21:576. [PMID: 34011301 DOI: 10.1186/s12885-021-08336-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
581 Maruki Y, Morizane C, Arai Y, Ikeda M, Ueno M, Ioka T, Naganuma A, Furukawa M, Mizuno N, Uwagawa T, Takahara N, Kanai M, Asagi A, Shimizu S, Miyamoto A, Yukisawa S, Kadokura M, Kojima Y, Furuse J, Nakajima TE, Sudo K, Kobayashi N, Hama N, Yamanaka T, Shibata T, Okusaka T. Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study). J Gastroenterol 2021;56:250-60. [PMID: 33106918 DOI: 10.1007/s00535-020-01735-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
582 Adhikaree J, Madhusudan S. Is there a role for second-line platinum re-challenge in advanced biliary tract cancers? Med Oncol 2014;31:46. [PMID: 24913810 DOI: 10.1007/s12032-014-0046-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
583 Zhang G, Gong S, Pang L, Hou L, He W. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study. Front Oncol 2021;11:659217. [PMID: 34012920 DOI: 10.3389/fonc.2021.659217] [Reference Citation Analysis]
584 Salati M, Rizzo A, Merz V, Messina C, Francesco C, Gelsomino F, Spallanzani A, Ricci AD, Palloni A, Frega G, De Lorenzo S, Carotenuto P, Pettorelli E, Benatti S, Luppi G, Melisi D, Brandi G, Dominici M. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. Expert Rev Gastroenterol Hepatol 2021;:1-7. [PMID: 34890512 DOI: 10.1080/17474124.2022.2017772] [Reference Citation Analysis]
585 Bergquist JR, Ivanics T, Storlie CB, Groeschl RT, Tee MC, Habermann EB, Smoot RL, Kendrick ML, Farnell MB, Roberts LR. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. J Surg Oncol. 2016;114:475-482. [PMID: 27439662 DOI: 10.1002/jso.24381] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
586 Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS. Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity. Dis Model Mech 2018;11:dmm033050. [PMID: 29666220 DOI: 10.1242/dmm.033050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
587 Solomon BL, Garrido-Laguna I. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncol 2018;14:947-62. [PMID: 29542354 DOI: 10.2217/fon-2017-0597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
588 Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2015;41:120-127. [PMID: 25449754 DOI: 10.1016/j.ejso.2014.09.007] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 11.6] [Reference Citation Analysis]
589 Ghidini M, Cascione L, Carotenuto P, Lampis A, Trevisani F, Previdi MC, Hahne JC, Said-Huntingford I, Raj M, Zerbi A, Mescoli C, Cillo U, Rugge M, Roncalli M, Torzilli G, Rimassa L, Santoro A, Valeri N, Fassan M, Braconi C. Characterisation of the immune-related transcriptome in resected biliary tract cancers. Eur J Cancer 2017;86:158-65. [PMID: 28988016 DOI: 10.1016/j.ejca.2017.09.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
590 Ling S, Xie H, Yang F, Shan Q, Dai H, Zhuo J, Wei X, Song P, Zhou L, Xu X, Zheng S. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. J Hematol Oncol. 2017;10:59. [PMID: 28241849 DOI: 10.1186/s13045-017-0424-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
591 Lindnér P, Rizell M, Hafström L. The impact of changed strategies for patients with cholangiocarcinoma in this millenium. HPB Surg 2015;2015:736049. [PMID: 25788760 DOI: 10.1155/2015/736049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
592 Koh M, Park JH, Yoo C, Yoon SM, Jung J, Ryoo BY, Chang HM, Kim KP, Jeong JH, Kim JH. Radiation therapy for recurrent extrahepatic bile duct cancer. PLoS One 2021;16:e0253285. [PMID: 34133471 DOI: 10.1371/journal.pone.0253285] [Reference Citation Analysis]
593 Kida M, Miyazawa S, Iwai T, Ikeda H, Takezawa M, Kikuchi H, Watanabe M, Imaizumi H, Koizumi W. Recent advances of biliary stent management. Korean J Radiol. 2012;13 Suppl 1:S62-S66. [PMID: 22563289 DOI: 10.3348/kjr.2012.13.s1.s62] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
594 Yang JD, Kim B, Sanderson SO, Sauver JS, Yawn BP, Larson JJ, Therneau TM, Roberts LR, Gores GJ, Kim WR. Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. Am J Gastroenterol. 2012;107:1256-1262. [PMID: 22751468 DOI: 10.1038/ajg.2012.173] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
595 Yang MH, Lee KT, Yang S, Lee JK, Lee KH, Moon IH, Rhee JC. Guggulsterone enhances antitumor activity of gemcitabine in gallbladder cancer cells through suppression of NF-κB. J Cancer Res Clin Oncol 2012;138:1743-51. [PMID: 22699931 DOI: 10.1007/s00432-012-1254-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
596 Sasaki T, Takeda T, Okamoto T, Ozaka M, Sasahira N. Chemotherapy for Biliary Tract Cancer in 2021. J Clin Med 2021;10:3108. [PMID: 34300274 DOI: 10.3390/jcm10143108] [Reference Citation Analysis]
597 Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov 2019;9:1064-79. [PMID: 31109923 DOI: 10.1158/2159-8290.CD-19-0182] [Cited by in Crossref: 96] [Cited by in F6Publishing: 53] [Article Influence: 32.0] [Reference Citation Analysis]
598 Kim J, Kim H, Lee JC, Kim JW, Paik WH, Lee SH, Hwang JH, Ryu JK, Kim YT. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. PLoS One 2018;13:e0209104. [PMID: 30557411 DOI: 10.1371/journal.pone.0209104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
599 Lee JH, Yu SE, Kim KH, Yu MH, Jeong IH, Cho JY, Park SJ, Lee WJ, Han SS, Kim TH, Hong EK, Woo SM, Yoo BC. Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: a useful tool for innovative screening programs and predictive strategies in healthcare. EPMA J 2018;9:287-97. [PMID: 30174764 DOI: 10.1007/s13167-018-0147-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
600 Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer 2020;8:e000564. [PMID: 32461347 DOI: 10.1136/jitc-2020-000564] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 27.0] [Reference Citation Analysis]
601 Yu Y, Chen Q, Zhang X, Yang J, Lin K, Ji C, Xu A, Yang L, Miao L. Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression. Cancer Sci 2020;111:2297-309. [PMID: 32378752 DOI: 10.1111/cas.14447] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
602 Sio TT, Martenson JA Jr, Haddock MG, Novotny PJ, Gores GJ, Alberts SR, Miller RC, Heimbach JK, Rosen CB. Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma. Am J Clin Oncol 2016;39:271-5. [PMID: 24921218 DOI: 10.1097/COC.0000000000000056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
603 Poddubskaya EV, Baranova MP, Allina DO, Smirnov PY, Albert EA, Kirilchev AP, Aleshin AA, Sekacheva MI, Suntsova MV. Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma. Exp Hematol Oncol 2018;7:21. [PMID: 30202637 DOI: 10.1186/s40164-018-0113-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
604 Kiesslich T, Mayr C, Wachter J, Bach D, Fuereder J, Wagner A, Alinger B, Pichler M, Di Fazio P, Ocker M. Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer. Mol Cell Biochem. 2014;396:257-268. [PMID: 25064451 DOI: 10.1007/s11010-014-2161-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
605 Wang D, Yang X, Long J, Lin J, Mao J, Xie F, Wang Y, Wang Y, Xun Z, Bai Y, Yang X, Guan M, Pan J, Seery S, Sang X, Zhao H. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study. Front Oncol 2021;11:646979. [PMID: 33912461 DOI: 10.3389/fonc.2021.646979] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
606 Altman AM, Kizy S, Marmor S, Hui JYC, Tuttle TM, Jensen EH, Denbo JW. Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus? Hepatobiliary Surg Nutr 2020;9:577-86. [PMID: 33163508 DOI: 10.21037/hbsn.2019.06.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
607 Lamarca A, Kapacee Z, Breeze M, Bell C, Belcher D, Staiger H, Taylor C, McNamara MG, Hubner RA, Valle JW. Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers.J Clin Med. 2020;9. [PMID: 32899345 DOI: 10.3390/jcm9092854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
608 Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014;21:3827-3834. [PMID: 24889489 DOI: 10.1245/s10434-014-3828-x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 10.1] [Reference Citation Analysis]
609 Hornberger J, Degtiar I, Gutierrez H, Shewade A, Henner WD, Becker S, Varadhachary G, Raab S. Cost-effectiveness of gene-expression profiling for tumor-site origin. Value Health 2013;16:46-56. [PMID: 23337215 DOI: 10.1016/j.jval.2012.09.005] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
610 Kim R, Coppola D, Wang E, Chang YD, Kim Y, Anaya D, Kim DW. Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma. Oncotarget 2018;9:23366-72. [PMID: 29805739 DOI: 10.18632/oncotarget.25163] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
611 Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120:165-171. [PMID: 30420614 DOI: 10.1038/s41416-018-0334-0] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 27.5] [Reference Citation Analysis]
612 Park HS, Park JS, Chun YJ, Roh YH, Moon J, Chon HJ, Choi HJ, Park JS, Lee DK, Lee SJ, Yoon DS, Jeung HC. Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer. Cancer Res Treat 2017;49:1127-39. [PMID: 28161931 DOI: 10.4143/crt.2016.538] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
613 Caparica R, Lengelé A, Bekolo W, Hendlisz A. FOLFIRI as second-line treatment of metastatic biliary tract cancer patients. Autops Case Rep 2019;9:e2019087. [PMID: 31528622 DOI: 10.4322/acr.2019.087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
614 Yang W, Li Y, Song X, Xu J, Xie J. Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing. Oncotarget 2017;8:26591-9. [PMID: 28427159 DOI: 10.18632/oncotarget.15721] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
615 Sasaki H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. Br J Cancer 2014;111:1275-84. [PMID: 25032731 DOI: 10.1038/bjc.2014.399] [Cited by in Crossref: 19] [Cited by in F6Publishing: 64] [Article Influence: 2.4] [Reference Citation Analysis]
616 Lin R, Zhan M, Yang L, Wang H, Shen H, Huang S, Huang X, Xu S, Zhang Z, Li W, Liu Q, Shi Y, Chen W, Yu J, Wang J. Deoxycholic acid modulates the progression of gallbladder cancer through N6-methyladenosine-dependent microRNA maturation. Oncogene 2020;39:4983-5000. [PMID: 32514152 DOI: 10.1038/s41388-020-1349-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
617 Chauhan A, House MG, Pitt HA, Nakeeb A, Howard TJ, Zyromski NJ, Schmidt CM, Ball CG, Lillemoe KD. Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma. HPB (Oxford). 2011;13:139-147. [PMID: 21241432 DOI: 10.1111/j.1477-2574.2010.00262.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
618 Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019;5:824-830. [PMID: 30998813 DOI: 10.1001/jamaoncol.2019.0270] [Cited by in Crossref: 105] [Cited by in F6Publishing: 100] [Article Influence: 52.5] [Reference Citation Analysis]
619 Bi C, Liu M, Rong W, Wu F, Zhang Y, Lin S, Liu Y, Wu J, Wang L. High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study. BMC Cancer 2019;19:213. [PMID: 30849962 DOI: 10.1186/s12885-019-5429-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
620 Yashima Y, Sato S, Kawai T, Sugimoto T, Sato T, Kanda M, Obi S. Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma. Hepatol Int 2015;9:142-8. [PMID: 25788388 DOI: 10.1007/s12072-014-9583-z] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
621 Zhu AX, Knox JJ. Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues. Oncologist. 2012;17:1504-1507. [PMID: 23220842 DOI: 10.1634/theoncologist.2012-0432] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
622 Nishikubo M, Shimomura Y, Hiramoto N, Sawamura N, Yamaguchi T, Hara S, Ishikawa T. Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report. BMC Nephrol 2021;22:175. [PMID: 33980166 DOI: 10.1186/s12882-021-02386-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
623 Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget 2016;7:58007-21. [PMID: 27517322 DOI: 10.18632/oncotarget.11157] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
624 Zane KE, Cloyd JM, Mumtaz KS, Wadhwa V, Makary MS. Metastatic disease to the liver: Locoregional therapy strategies and outcomes. World J Clin Oncol 2021; 12(9): 725-745 [PMID: 34631439 DOI: 10.5306/wjco.v12.i9.725] [Reference Citation Analysis]
625 Bokemeyer A, Matern P, Bettenworth D, Cordes F, Nowacki TM, Heinzow H, Kabar I, Schmidt H, Ullerich H, Lenze F. Endoscopic Radiofrequency Ablation Prolongs Survival of Patients with Unresectable Hilar Cholangiocellular Carcinoma - A Case-Control Study.Sci Rep. 2019;9:13685. [PMID: 31548703 DOI: 10.1038/s41598-019-50132-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
626 Saboo SS, Krajewski KM, Jagannathan JP, O'Regan KN, Odze R, Ramaiya N, Wolpin BM. Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma. Cancer Imaging 2011;11:37-41. [PMID: 21507775 DOI: 10.1102/1470-7330.2011.0009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
627 Moik F, Riedl JM, Winder T, Terbuch A, Rossmann CH, Szkandera J, Bauernhofer T, Kasparek AK, Schaberl-Moser R, Reicher A, Prinz F, Pichler M, Stöger H, Stotz M, Gerger A, Posch F. Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis. Sci Rep 2019;9:5548. [PMID: 30944390 DOI: 10.1038/s41598-019-42069-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
628 Ishii N, Suzuki H, Tsukagoshi M, Watanabe A, Kubo N, Araki K, Wada S, Kuwano H. Giant Cholangiolocellular Carcinoma With Early Recurrence That Was Difficult to Distinguish From Cholangiocellular Carcinoma: Report of a Case. Int Surg 2015;100:1111-6. [PMID: 26414834 DOI: 10.9738/INTSURG-D-14-00215.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
629 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
630 O'Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, Rossi RM, Zhu AX, Land H, Bardeesy N, Hezel AF. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 2012;72:1557-1567. [PMID: 22266220 DOI: 10.1158/0008-5472.can-11-3596] [Cited by in Crossref: 109] [Cited by in F6Publishing: 71] [Article Influence: 10.9] [Reference Citation Analysis]
631 Seidensticker R, Seidensticker M, Doegen K, Mohnike K, Schütte K, Stübs P, Kettner E, Pech M, Amthauer H, Ricke J. Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma. Gastroenterol Res Pract 2016;2016:8732521. [PMID: 26966431 DOI: 10.1155/2016/8732521] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
632 Karlsson-Parra A, Kovacka J, Heimann E, Jorvid M, Zeilemaker S, Longhurst S, Suenaert P. Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration. Pharm Res 2018;35:156. [PMID: 29904904 DOI: 10.1007/s11095-018-2438-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
633 Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, Pouptsis A, Pinato DJ, Rimassa L. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers (Basel) 2020;12:E3370. [PMID: 33202975 DOI: 10.3390/cancers12113370] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
634 Zhao DY, Lim KH. Current biologics for treatment of biliary tract cancers. J Gastrointest Oncol 2017;8:430-40. [PMID: 28736630 DOI: 10.21037/jgo.2017.05.04] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
635 Lee-Ying R, Ahmed O, Ahmed S, Ahmed S, Bathe OF, Brunet B, Dawson L, Davies J, Gordon V, Hebbard P, Kasnik J, Kim CA, Le D, Lee MKC, Lim H, McGhie JP, Mulder K, Park J, Renouf D, Tam V, Visser R, Wong RPW, Zaidi A, Doll C. Report from the 21st Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; 20-21 September 2019. Curr Oncol 2021;28:3629-48. [PMID: 34590606 DOI: 10.3390/curroncol28050310] [Reference Citation Analysis]
636 Lowery MA, Bradley M, Chou JF, Capanu M, Gerst S, Harding JJ, Dika IE, Berger M, Zehir A, Ptashkin R, Wong P, Rasalan-Ho T, Yu KH, Cercek A, Morgono E, Salehi E, Valentino E, Hollywood E, O'Reilly EM, Abou-Alfa GK. Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. Clin Cancer Res 2019;25:937-45. [PMID: 30563938 DOI: 10.1158/1078-0432.CCR-18-1927] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
637 Fukuda Y, Asaoka T, Eguchi H, Yokota Y, Kubo M, Kinoshita M, Urakawa S, Iwagami Y, Tomimaru Y, Akita H, Noda T, Gotoh K, Kobayashi S, Hirata M, Wada H, Mori M, Doki Y. Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma. Cancer Sci. 2020;111:323-333. [PMID: 31799781 DOI: 10.1111/cas.14267] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
638 Marin JJG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, Segatto O, Vogel A, Macias RIR, Rodrigues PM, Casta A, Mertens J, Rodrigues CMP, Fernandez-Barrena MG, Da Silva Ruivo A, Marzioni M, Mentrasti G, Acedo P, Munoz-Garrido P, Cardinale V, Banales JM, Valle JW, Bridgewater J, Braconi C; working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA). Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer 2020;123:1047-59. [PMID: 32694694 DOI: 10.1038/s41416-020-0987-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
639 Marin JJG, Sanchon-Sanchez P, Cives-Losada C, Del Carmen S, González-Santiago JM, Monte MJ, Macias RIR. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers (Basel) 2021;13:2358. [PMID: 34068398 DOI: 10.3390/cancers13102358] [Reference Citation Analysis]
640 Ghosh J, Ganguly S, Dabkara D, Biswas B, Chatterjee A, Mukhopadhyay S, Chandra A, Sen S, Dey D. Metachronous muscle metastasis in a case of metastatic gallbladder cancer with TP35 gene mutation: A rare case report. South Asian J Cancer 2019;8:240. [PMID: 31807487 DOI: 10.4103/sajc.sajc_139_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
641 Zender L, Malek NP. [Diagnostics and treatment of cholangiocellular carcinoma]. Internist (Berl) 2016;57:1191-205. [PMID: 27822622 DOI: 10.1007/s00108-016-0128-5] [Reference Citation Analysis]
642 Tovoli F, Garajová I, Gelsomino F, Iavarone M, Federico P, Salati M, Corianò M, Caputo F, De Lorenzo S, Granito A, Renzulli M, Daniele B, Piscaglia F. Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second-line clinical trials. Liver Int 2021. [PMID: 34826193 DOI: 10.1111/liv.15117] [Reference Citation Analysis]
643 Buckarma EH, Werneburg NW, Conboy CB, Kabashima A, O'Brien DR, Wang C, Rizvi S, Smoot RL. The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma. Mol Cancer Res 2020;18:1574-88. [PMID: 32646966 DOI: 10.1158/1541-7786.MCR-20-0165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
644 Paprottka KJ, Galiè F, Ingrisch M, Geith T, Ilhan H, Todica A, Michl M, Nadjiri J, Paprottka PM. Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma-An Evaluation of Predictors. Cancers (Basel) 2021;13:5399. [PMID: 34771563 DOI: 10.3390/cancers13215399] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
645 Mizusawa J, Morizane C, Okusaka T, Katayama H, Ishii H, Fukuda H, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol. 2016;46:385-388. [PMID: 27025903 DOI: 10.1093/jjco/hyv213] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
646 Goto T, Saito H, Sasajima J, Kawamoto T, Fujinaga A, Utsumi T, Yanagawa N, Hiramatsu K, Takamura A, Sato H, Fujibayashi S, Fujiya M. High Response Rate and Prolonged Survival of Unresectable Biliary Tract Cancer Treated With a New Combination Therapy Consisting of Intraarterial Chemotherapy Plus Radiotherapy. Front Oncol 2020;10:597813. [PMID: 33312956 DOI: 10.3389/fonc.2020.597813] [Reference Citation Analysis]
647 McKay SC, Unger K, Pericleous S, Stamp G, Thomas G, Hutchins RR, Spalding DR. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford). 2011;13:309-319. [PMID: 21492330 DOI: 10.1111/j.1477-2574.2010.00286.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
648 Gong J, Cho M, Fakih M. Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. J Gastrointest Oncol 2017;8:314-23. [PMID: 28480070 DOI: 10.21037/jgo.2016.09.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
649 Pinter M, Sieghart W, Reisegger M, Wrba F, Peck-Radosavljevic M. Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. Wien Klin Wochenschr 2011;123:61-4. [PMID: 21240686 DOI: 10.1007/s00508-010-1522-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
650 Soni K, Kumar T, Pandey M. Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature. World J Surg Oncol 2020;18:153. [PMID: 32622356 DOI: 10.1186/s12957-020-01934-4] [Reference Citation Analysis]
651 Benavides M, Antón A, Gallego J, Gómez MA, Jiménez-Gordo A, La Casta A, Laquente B, Macarulla T, Rodríguez-Mowbray JR, Maurel J. Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol 2015;17:982-7. [PMID: 26607930 DOI: 10.1007/s12094-015-1436-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
652 Yang Y, Li J, Yao L, Wu L. Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR. Front Cell Dev Biol 2021;9:710721. [PMID: 34805140 DOI: 10.3389/fcell.2021.710721] [Reference Citation Analysis]
653 Goetze TO, Bechstein WO, Bankstahl US, Keck T, Königsrainer A, Lang SA, Pauligk C, Piso P, Vogel A, Al-Batran SE. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial. BMC Cancer 2020;20:122. [PMID: 32059704 DOI: 10.1186/s12885-020-6610-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
654 Ma N, Cheng H, Qin B, Zhong R, Wang B. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer 2015;15:615. [PMID: 26337466 DOI: 10.1186/s12885-015-1617-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
655 Brown KM, Parmar AD, Geller DA. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2014;23:231-246. [PMID: 24560108 DOI: 10.1016/j.soc.2013.10.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
656 Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
657 Koedijk MS, Heijmen BJM, Groot Koerkamp B, Eskens FALM, Sprengers D, Poley JW, van Gent DC, van der Laan LJW, van der Holt B, Willemssen FEJA, Méndez Romero A. Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study. BMJ Open 2018;8:e020731. [PMID: 30327398 DOI: 10.1136/bmjopen-2017-020731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
658 Saletti P, Zaniboni A. Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. J Gastrointest Oncol 2018;9:377-89. [PMID: 29755778 DOI: 10.21037/jgo.2018.01.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
659 Jia AY, Popovic A, Mohan AA, Zorzi J, Griffith P, Kim AK, Anders RA, Burkhart RA, Lafaro K, Georgiades C, Azad NS, Liddell RP, Baretti M, Kamel IR, Narang A, Yarchoan M, Meyer J. Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control 2021;28:10732748211009945. [PMID: 33882707 DOI: 10.1177/10732748211009945] [Reference Citation Analysis]
660 Neeff HP, Holzner PA, Menzel M, Bronsert P, Klock A, Lang SA, Fichtner-Feigl S, Hopt UT, Makowiec F. [Intrahepatic cholangiocarcinoma : Results after 84 resections]. Chirurg 2018;89:374-80. [PMID: 29464308 DOI: 10.1007/s00104-018-0609-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
661 Kang MJ, Song Y, Jang JY, Han IW, Kim SW. Role of radical surgery in patients with stage IV gallbladder cancer. HPB (Oxford). 2012;14:805-811. [PMID: 23134181 DOI: 10.1111/j.1477-2574.2012.00544.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
662 Moureau-Zabotto L, Turrini O, Resbeut M, Raoul JL, Giovannini M, Poizat F, Piana G, Delpero JR, Bertucci F. Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma. BMC Cancer 2013;13:568. [PMID: 24299517 DOI: 10.1186/1471-2407-13-568] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
663 Creutzfeldt A, Suling A, Oechsle K, Mehnert A, Atanackovic D, Kripp M, Arnold D, Stein A, Quidde J. Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. BMC Palliat Care 2016;15:25. [PMID: 26928745 DOI: 10.1186/s12904-016-0101-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
664 Gairing SJ, Thol F, Müller L, Hahn F, Thomaidis T, Czauderna C, Bartsch F, Pitton MB, Marquardt JU, Wörns MA, Galle PR, Moehler M, Weinmann A, Kloeckner R, Foerster F. The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2732. [PMID: 34205670 DOI: 10.3390/jcm10122732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
665 Postlewait LM, Ethun CG, Le N, Pawlik TM, Buettner S, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RCG, Scoggins C, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Vitiello G, Cardona K, Maithel SK. Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. HPB (Oxford) 2016;18:793-9. [PMID: 27506989 DOI: 10.1016/j.hpb.2016.07.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
666 Soares KC, Jarnagin WR. The Landmark Series: Hilar Cholangiocarcinoma. Ann Surg Oncol 2021;28:4158-70. [PMID: 33829358 DOI: 10.1245/s10434-021-09871-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
667 Li Z, Jiang X, Huang L, Li J, Ji D, Xu Y, Leng K, Cui Y. Up-regulation of ZFAS1 indicates dismal prognosis for cholangiocarcinoma and promotes proliferation and metastasis by modulating USF1 via miR-296-5p. J Cell Mol Med 2019;23:8258-68. [PMID: 31565837 DOI: 10.1111/jcmm.14698] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
668 Hennedige TP, Neo WT, Venkatesh SK. Imaging of malignancies of the biliary tract- an update. Cancer Imaging 2014;14:14. [PMID: 25608662 DOI: 10.1186/1470-7330-14-14] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
669 Urtasun N, Boces-Pascual C, Boix L, Bruix J, Pastor-Anglada M, Pérez-Torras S. Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. Oncotarget 2017;8:90185-96. [PMID: 29163820 DOI: 10.18632/oncotarget.21624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
670 Li J, Moustafa M, Linecker M, Lurje G, Capobianco I, Baumgart J, Ratti F, Rauchfuss F, Balci D, Fernandes E, Montalti R, Robles-Campos R, Bjornsson B, Topp SA, Fronek J, Liu C, Wahba R, Bruns C, Brunner SM, Schlitt HJ, Heumann A, Stüben BO, Izbicki JR, Bednarsch J, Gringeri E, Fasolo E, Rolinger J, Kristek J, Hernandez-Alejandro R, Schnitzbauer A, Nuessler N, Schön MR, Voskanyan S, Petrou AS, Hahn O, Soejima Y, Vicente E, Castro-Benitez C, Adam R, Tomassini F, Troisi RI, Kantas A, Oldhafer KJ, Ardiles V, de Santibanes E, Malago M, Clavien PA, Vivarelli M, Settmacher U, Aldrighetti L, Neumann U, Petrowsky H, Cillo U, Lang H, Nadalin S. ALPPS for Locally Advanced Intrahepatic Cholangiocarcinoma: Did Aggressive Surgery Lead to the Oncological Benefit? An International Multi-center Study. Ann Surg Oncol 2020;27:1372-84. [PMID: 32002719 DOI: 10.1245/s10434-019-08192-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
671 Xu S, Jiang C, Lin R, Wang X, Hu X, Chen W, Chen X, Chen T. Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy. J Exp Clin Cancer Res 2021;40:373. [PMID: 34823564 DOI: 10.1186/s13046-021-02186-0] [Reference Citation Analysis]
672 Limpawattana P, Wirasorn K, Sookprasert A, Sawanyawisuth K, Titapun A, Luvira V, Khuntikeo N, Chindaprasirt J. Frailty Syndrome in Biliary Tract Cancer Patients: Prevalence and Associated Factors. Asian Pac J Cancer Prev 2019;20:1497-501. [PMID: 31127914 DOI: 10.31557/APJCP.2019.20.5.1497] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
673 Iyer RV, Acquisto SG, Bridgewater JA, Choti MA, Hong TS, Kis B, Mead PA, Parikh ND, Roberts LR, Roberts R, Salem R, Sicklick JK, Siegel RS, Whisenant JR, Cherepanov D, Broder MS, Valle JW. Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters using the Modified RAND/UCLA Delphi Process. Cancers (Basel) 2020;12:E2375. [PMID: 32825784 DOI: 10.3390/cancers12092375] [Reference Citation Analysis]
674 Ulahannan SV, Rahma OE, Duffy AG, Makarova-Rusher OV, Kurtoglu M, Liewehr DJ, Steinberg SM, Greten TF. Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. Hepat Oncol 2015;2:39-50. [PMID: 25685318 DOI: 10.2217/hep.14.36] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
675 Hernandez DL, Restrepo J, Garcia Mora M. Peritoneal Metastasis of Cholangiocarcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy at the Instituto Nacional de Cancerología, Colombia. Cureus 2020;12:e6697. [PMID: 32117649 DOI: 10.7759/cureus.6697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
676 Jansen H, Pape UF, Utku N. A review of systemic therapy in biliary tract carcinoma. J Gastrointest Oncol 2020;11:770-89. [PMID: 32953160 DOI: 10.21037/jgo-20-203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
677 Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol 2016;34:219-26. [PMID: 26503201 DOI: 10.1200/JCO.2015.61.3778] [Cited by in Crossref: 121] [Cited by in F6Publishing: 59] [Article Influence: 17.3] [Reference Citation Analysis]
678 Malenica I, Donadon M, Lleo A. Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. Cancers (Basel) 2020;12:E2190. [PMID: 32781527 DOI: 10.3390/cancers12082190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
679 Sakamoto Y, Yamagishi S, Okusaka T, Ojima H. Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines. Cells 2019;8:E1026. [PMID: 31484399 DOI: 10.3390/cells8091026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
680 Boyd LNC, Peters GJ, Kazemier G, Giovannetti E. NUC-1031 in biliary tract cancer: from bench to bedside and back? Cancer Chemother Pharmacol 2020;85:1011-4. [PMID: 32476108 DOI: 10.1007/s00280-020-04080-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
681 Li X, Gao L, Qiu M, Cao D. Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation. Onco Targets Ther 2021;14:2815-9. [PMID: 33911878 DOI: 10.2147/OTT.S303594] [Reference Citation Analysis]
682 Ito T, Shinkawa H, Takemura S, Tanaka S, Nishioka T, Miyazaki T, Ishihara A, Kubo S. Impact of the Preoperative C-reactive Protein to Albumin Ratio on the Long-Term Outcomes of Hepatic Resection for Intrahepatic Cholangiocarcinoma. Asian Pac J Cancer Prev 2020;21:2373-9. [PMID: 32856868 DOI: 10.31557/APJCP.2020.21.8.2373] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
683 Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015;5:1040-1048. [PMID: 26109333 DOI: 10.1158/2159-8290.cd-15-0274.cell-free] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
684 Huang P, Zhou Y, Chen Y. Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review. J Gastrointest Cancer 2021. [PMID: 34312770 DOI: 10.1007/s12029-021-00637-7] [Reference Citation Analysis]
685 Haga H, Patel T. Molecular diagnosis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2015;22:114-23. [PMID: 25267595 DOI: 10.1002/jhbp.156] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
686 Miyahara Y, Takashi S, Shimizu Y, Ohtsuka M. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer. World J Surg Oncol 2020;18:78. [PMID: 32321522 DOI: 10.1186/s12957-020-01847-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
687 Martin Huertas R, Fuentes-Mateos R, Serrano Domingo JJ, Corral de la Fuente E, Rodríguez-Garrote M. Albumin-bound paclitaxel as new treatment for metastatic cholangiocarcinoma: A case report. World J Clin Oncol 2020; 11(10): 844-853 [PMID: 33200077 DOI: 10.5306/wjco.v11.i10.844] [Reference Citation Analysis]
688 Yu Z, Cheng H, Zhu H, Cao M, Lu C, Bao S, Pan Y, Li Y. Salinomycin enhances doxorubicin sensitivity through reversing the epithelial-mesenchymal transition of cholangiocarcinoma cells by regulating ARK5. Braz J Med Biol Res 2017;50:e6147. [PMID: 28832761 DOI: 10.1590/1414-431X20176147] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
689 Aktas G, Kus T, Balkan A, Metin T, Gulsen MT, Abali H. Prognostic factors in patients with advanced extrahepatic cholangiocarcinoma: A single center experience. Medicine (Baltimore) 2019;98:e14556. [PMID: 30813168 DOI: 10.1097/MD.0000000000014556] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
690 Storr SJ, Zaitoun AM, Arora A, Durrant LG, Lobo DN, Madhusudan S, Martin SG. Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla. BMC Cancer 2012;12:511. [PMID: 23140395 DOI: 10.1186/1471-2407-12-511] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
691 Romiti A, Barucca V, Zullo A, Sarcina I, Di Rocco R, D’Antonio C, Latorre M, Marchetti P. Tumors of ampulla of Vater: A case series and review of chemotherapy options. World J Gastrointest Oncol 2012; 4(3): 60-67 [PMID: 22468185 DOI: 10.4251/wjgo.v4.i3.60] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
692 Mao J, Yang X, Lin J, Yang X, Wang D, Zhang L, Bai Y, Bian J, Long J, Xie F, Huang H, Sang X, Chen S, Zhao H. Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma. J Cancer 2021;12:1555-62. [PMID: 33532001 DOI: 10.7150/jca.53482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
693